[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 2468
1. Ali TZ, Zakowski MF, Yung RC, Burroughs FH, Ali SZ: Exfoliative sputum cytology of cancers metastatic to the lung. Diagn Cytopathol; 2005 Sep;33(3):147-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Exfoliative sputum cytology of cancers metastatic to the lung.
  • Although largely replaced by fine-needle aspiration (FNA) and bronchoscopy, cytological examination of sputum for exfoliated malignant cells still is considered a valuable initial diagnostic test in patients presenting with a lung mass.
  • Thirty-five cases of secondary/metastatic tumors involving the lung and diagnosed on sputum were retrospectively reviewed from our cytopathology files for a period of 22 yr (1980-2001).
  • Cytological diagnoses included colonic adenocarcinoma (7 cases); non-Hodgkin's lymphoma (NHL; 5 cases); malignant melanoma (MM; 5 cases); breast carcinoma (5 cases); Hodgkin's lymphoma (HL; 3 cases); pancreatic adenocarcinoma (2 cases); prostatic adenocarcinoma (2 cases); and 1 case each of urothelial carcinoma, endometrial carcinoma, renal cell carcinoma, hepatic small-cell carcinoma, squamous-cell carcinoma (cervix), and leiomyosarcoma (LMS).
  • In non-lymphoid tumors (27 cases), isolated single malignant cells were seen in 7 (26%) cases (all cases of MM and prostatic adenocarcinoma), whereas 20 (74%) cases displayed fragments with intact tumor architecture.
  • Overall, only 10/35 (29%) cases showed noticeable tumor-cell necrosis.
  • In one case (LMS), cell block sections were used for immunoperoxidase (IPOX) studies with positive staining for desmin and actin.
  • Exfoliation of cancer cells in sputum from secondary tumors in the lung is a rare phenomenon in current-day practice, with metastatic colonic adenocarcinoma seen most commonly.
  • [MeSH-major] Lung Neoplasms / diagnosis. Lung Neoplasms / secondary. Neoplasm Metastasis / diagnosis. Sputum / cytology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 Wiley-Liss, Inc.
  • (PMID = 16078247.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


2. Matsumoto S, Iwakawa R, Kohno T, Suzuki K, Matsuno Y, Yamamoto S, Noguchi M, Shimizu E, Yokota J: Frequent EGFR mutations in noninvasive bronchioloalveolar carcinoma. Int J Cancer; 2006 May 15;118(10):2498-504
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frequent EGFR mutations in noninvasive bronchioloalveolar carcinoma.
  • Mutations of the epidermal growth factor receptor gene (EGFR) have been reported to be present in a considerable fraction of lung adenocarcinomas showing dramatic response to EGFR tyrosine kinase inhibitors.
  • To clarify pathogenic significance of the mutations for the development of lung adenocarcinoma, we investigated stage I lung adenocarcinomas for the mutations.
  • In particular, among the stage I cases, the mutations were detected in 17 of 42 small-sized adenocarcinomas (<or=2 cm in diameter) (40%), including 7 of 11 noninvasive bronchioloalveolar carcinomas (BACs) (64%) and 7 of 25 invasive adenocarcinomas with BAC components (28%).
  • Second, 26 cases of laser capture microdissected small-sized adenocarcinomas, including 9 cases in the first analysis, were examined for the mutations.
  • EGFR mutations are present frequently in BACs, and are thus likely to be a critical genetic alteration for the formation of noninvasive lung adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma, Bronchiolo-Alveolar / genetics. Carcinoma, Non-Small-Cell Lung / genetics. Lung Neoplasms / genetics. Receptor, Epidermal Growth Factor / genetics

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 Wiley-Liss, Inc.
  • (PMID = 16353158.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


3. Sakao Y, Miyamoto H, Yamazaki A, Oh T, Fukai R, Shiomi K, Saito Y: Prognostic significance of metastasis to the highest mediastinal lymph node in nonsmall cell lung cancer. Ann Thorac Surg; 2006 Jan;81(1):292-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of metastasis to the highest mediastinal lymph node in nonsmall cell lung cancer.
  • BACKGROUND: We have tried to clarify the prognostic significance of metastasis to the highest mediastinal (HM) lymph node in patients with N2 lung cancer who underwent complete dissection of superior mediastinal (including HM) lymph nodes.
  • METHODS: This study analyzed 53 patients with N2 nonsmall cell lung cancer who underwent surgical procedures such as lobectomy plus hilar and mediastinal node dissection (T4, neoadjuvant therapy cases were excluded).
  • For patients whose cancer was in the left lung, we performed surgery through the median sternotomy in order to dissect superior mediastinal nodes.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / secondary. Lung Neoplasms / mortality. Lymphatic Metastasis. Mediastinum
  • [MeSH-minor] Adenocarcinoma / blood. Adenocarcinoma / mortality. Adenocarcinoma / secondary. Adenocarcinoma / surgery. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / blood. Carcinoembryonic Antigen / analysis. Carcinoma, Squamous Cell / blood. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / secondary. Carcinoma, Squamous Cell / surgery. Female. Humans. Life Tables. Lymph Node Excision. Male. Middle Aged. Neoplasm Staging. Pneumonectomy. Prognosis. Survival Analysis. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Thorac Surg. 2006 Jan;81(1):297 [16368384.001]
  • (PMID = 16368383.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen
  •  go-up   go-down


Advertisement
4. Naito Y, Goto K, Nagai K, Ishii G, Nishimura M, Yoshida J, Hishida T, Nishiwaki Y: Vascular invasion is a strong prognostic factor after complete resection of node-negative non-small cell lung cancer. Chest; 2010 Dec;138(6):1411-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vascular invasion is a strong prognostic factor after complete resection of node-negative non-small cell lung cancer.
  • BACKGROUND: The seventh edition of TNM classification for non-small cell lung cancer (NSCLC) has been approved.
  • Thirty-two percent of patients were > 70 years, 44% were women, 78% had adenocarcinoma, 41% were never smokers, 39% smoked > 30 pack-years, and 31% had elevated serum CEA levels.
  • Vascular invasion was detected in 279 patients (33.8%) and more was observed in patients who were male, did not have adenocarcinoma, were smokers, and had elevated CEA levels.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / mortality. Carcinoma, Non-Small-Cell Lung / surgery. Lung Neoplasms / mortality. Lung Neoplasms / surgery. Neoplasm Invasiveness / pathology. Neovascularization, Pathologic / diagnosis


5. Fritzsche FR, Dahl E, Dankof A, Burkhardt M, Pahl S, Petersen I, Dietel M, Kristiansen G: Expression of AGR2 in non small cell lung cancer. Histol Histopathol; 2007 07;22(7):703-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of AGR2 in non small cell lung cancer.
  • We aimed to evaluate immunohistochemically the expression of the human Anterior Gradient-2 (AGR2), a gene which has recently been proposed as an oncogene for lung carcinoma development, in non small cell lung cancer and to correlate the findings to clinico-pathological data including patient survival.
  • Interestingly, this is the first study to demonstrate AGR2 expression in squamous cell carcinomas.
  • [MeSH-major] Adenocarcinoma / chemistry. Carcinoma, Non-Small-Cell Lung / chemistry. Carcinoma, Squamous Cell / chemistry. Lung Neoplasms / chemistry. Proteins / analysis


6. Castaño Z, Vergara-Irigaray N, Pajares MJ, Montuenga LM, Pio R: Expression of alpha CP-4 inhibits cell cycle progression and suppresses tumorigenicity of lung cancer cells. Int J Cancer; 2008 Apr 1;122(7):1512-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of alpha CP-4 inhibits cell cycle progression and suppresses tumorigenicity of lung cancer cells.
  • The protein alpha CP-4 (also known as hnRNP E4) is an RNA binding protein encoded by a gene at 3p21, one of the most common altered regions in lung cancer.
  • It has been proposed that alpha CP-4 may function as a lung tumor suppressor.
  • Lack of alpha CP-4 expression is frequent in highly proliferative lung tumors and correlates with alpha CP-4 allele losses.
  • The aim of this study was to evaluate the effect of alpha CP-4 on the tumorigenic capacity of lung cancer cells. alpha CP-4 expression was induced by transient transfection or stable infection with recombinant retroviruses.
  • Induction of alpha CP-4 expression caused cell cycle arrest in G(2)/M in 3 out of the 7 lung cancer cell lines studied, while no effect on apoptosis was observed.
  • Immunocytochemistry analysis of the xenograft tumors revealed an in vivo effect of alpha CP-4 on cell proliferation and no effect on apoptosis.
  • Finally, alpha CP-4 showed a subcellular localization different from alpha CP-4a, a splice variant that does not affect cell proliferation.
  • In conclusion, expression of alpha CP-4 can inhibit proliferation and tumorigenesis of lung cancer cells, both in vivo and in vitro, by delaying the progression of the cell cycle.
  • [MeSH-major] Apoptosis. Carcinoma, Non-Small-Cell Lung / metabolism. Cell Cycle. DNA Damage. Lung Neoplasms / metabolism. RNA-Binding Proteins / metabolism. Tumor Suppressor Proteins / metabolism
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma, Bronchiolo-Alveolar / metabolism. Animals. Blotting, Western. Carcinoid Tumor / metabolism. Carcinoma, Large Cell / metabolism. Carcinoma, Squamous Cell / metabolism. Chromosomes, Human, Pair 3. Female. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. In Situ Nick-End Labeling. Mice. Mice, Nude. Retroviridae. Reverse Transcriptase Polymerase Chain Reaction. Transfection. Transplantation, Heterologous

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17973258.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / PCBP4 protein, human; 0 / RNA-Binding Proteins; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


7. Mok T, Wu YL, Zhang L: A small step towards personalized medicine for non-small cell lung cancer. Discov Med; 2009 Dec;8(43):227-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A small step towards personalized medicine for non-small cell lung cancer.
  • Treatment outcome for advanced-stage non-small cell lung cancer (NSCLC) is limited by empiric administration of cytotoxic chemotherapy.
  • Recent advances in molecular genomics have revolutionized cancer management and, specifically, epidermal growth factor receptor (EGFR) mutation has become a potent biomarker for lung cancer, which predicts tumor response to and prolonged duration of disease control by EGFR tyrosine kinase inhibitors (TKI).
  • The Iressa Pan-Asia Study (IPASS) is a randomized phase III study comparing gefitinib (EGFR TKI) with paclitaxel/carboplatin (standard chemotherapy) in Asian non-/light smokers with adenocarcinoma.
  • This small step towards personalized medicine represents a paradigm shift in the management of NSCLC.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Precision Medicine / methods


8. Liptay MJ, D'amico TA, Nwogu C, Demmy TL, Wang XF, Gu L, Litle VR, Swanson SJ, Kohman LJ, Thoracic Surgery Subcommittee of the Cancer and Leukemia Group B: Intraoperative sentinel node mapping with technitium-99 in lung cancer: results of CALGB 140203 multicenter phase II trial. J Thorac Oncol; 2009 Feb;4(2):198-202
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraoperative sentinel node mapping with technitium-99 in lung cancer: results of CALGB 140203 multicenter phase II trial.
  • INTRODUCTION: Sentinel node mapping with radioactive technetium in non-small cell lung cancer has been shown to be feasible in several single institution reports.
  • METHODS: Patients with clinical stage I non-small cell lung cancer amenable to resection were candidates for this trial.
  • CONCLUSIONS: Intraoperative sentinel node mapping in lung cancer with radioisotope yielded lower accrual and worse accuracy than expected.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / secondary. Lung Neoplasms / pathology. Lymph Nodes / radionuclide imaging. Monitoring, Intraoperative. Radiopharmaceuticals. Technetium Tc 99m Sulfur Colloid
  • [MeSH-minor] Adenocarcinoma / secondary. Adenocarcinoma / surgery. Aged. Aged, 80 and over. Carcinoma, Large Cell / secondary. Carcinoma, Large Cell / surgery. Carcinoma, Squamous Cell / secondary. Carcinoma, Squamous Cell / surgery. Feasibility Studies. Female. Humans. Lymph Node Excision. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Prognosis. Risk Factors. Sentinel Lymph Node Biopsy. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19179896.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 556Q0P6PB1 / Technetium Tc 99m Sulfur Colloid
  •  go-up   go-down


9. Yang CJ, Wang CS, Hung JY, Huang HW, Chia YC, Wang PH, Weng CF, Huang MS: Pyrogallol induces G2-M arrest in human lung cancer cells and inhibits tumor growth in an animal model. Lung Cancer; 2009 Nov;66(2):162-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pyrogallol induces G2-M arrest in human lung cancer cells and inhibits tumor growth in an animal model.
  • Pyrogallol, a catechin compound, is an active component of Emblica officinalis extracts and has an anti-proliferative effect on some human cancer cell lines.
  • In our preliminary study, pyrogallol had highly cytotoxic effect on human lung cancer cell lines and less effect on human bronchial epithelium cell line.
  • This study was performed to investigate the beneficial effect of pyrogallol on human lung cancer cell lines - H441 (lung adenocarcinoma) and H520 (lung squamous cell carcinoma).
  • The MTT (cytotoxic) data showed the inhibition growth of lung cancer cells followed pyrogallol treatment.
  • The cell cycle of lung cancer cells was arrested in G2/M phase using flow cytometry.
  • Using Western blot analysis, the cell cycle related proteins - cyclin B1 and Cdc25c were decreased in a time-dependent manner and the phosphorylated Cdc2 (Thr14) was increased within 4h pyrogallol treatment.
  • Moreover, the higher cleavage of poly (ADP)-ribose polymerase (PARP), the increased of Bax concurrent with the decreased of Bcl-2 indicated that pyrogallol treatment resulted in apoptosis of lung cancer cells.
  • The cell apoptosis was also directly demonstrated using Annexin V-FITC and TUNEL stain.
  • Taken in vitro and in vivo studies together, these results suggest that pyrogallol can be developed as a promising anti-lung cancer drug particular for the non-small cell lung cancer (NSCLC).
  • [MeSH-major] Antineoplastic Agents / pharmacology. Cell Cycle / drug effects. Growth Inhibitors / pharmacology. Lung Neoplasms / drug therapy. Pyrogallol / pharmacology
  • [MeSH-minor] Adenocarcinoma / drug therapy. Animals. Carcinoma, Squamous Cell / drug therapy. Cell Cycle Proteins / drug effects. Cell Division / drug effects. Cell Line, Tumor. Cytotoxins / pharmacology. Disease Models, Animal. G2 Phase / drug effects. Humans. Mice. Mice, Nude

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. Pyrogallic acid .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19233505.001).
  • [ISSN] 1872-8332
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Cell Cycle Proteins; 0 / Cytotoxins; 0 / Growth Inhibitors; 01Y4A2QXY0 / Pyrogallol
  •  go-up   go-down


10. Yokomise H, Gotoh M, Okamoto T, Yamamoto Y, Ishikawa S, Liu D, Oka S, Huang CL: En bloc partial vertebrectomy for lung cancer invading the spine after induction chemoradiotherapy. Eur J Cardiothorac Surg; 2007 May;31(5):788-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] En bloc partial vertebrectomy for lung cancer invading the spine after induction chemoradiotherapy.
  • OBJECTIVE: The optimal surgical treatment for non-small cell lung cancer (NSCLC) with vertebral body invasion remains both controversial and challenging.
  • We reviewed our experiences of NSCLC with vertebral body invasion, in which we have performed induction chemoradiotherapy followed by lung resection with en bloc partial vertebrectomy.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / therapy. Lung Neoplasms / therapy. Spinal Neoplasms / surgery. Spine / surgery
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Adenocarcinoma / therapy. Aged. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Carcinoma, Squamous Cell / therapy. Combined Modality Therapy / methods. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Survival Analysis. Thoracic Surgical Procedures / methods. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17329115.001).
  • [ISSN] 1010-7940
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


11. Girard N, Deshpande C, Lau C, Finley D, Rusch V, Pao W, Travis WD: Comprehensive histologic assessment helps to differentiate multiple lung primary nonsmall cell carcinomas from metastases. Am J Surg Pathol; 2009 Dec;33(12):1752-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comprehensive histologic assessment helps to differentiate multiple lung primary nonsmall cell carcinomas from metastases.
  • The pathologic classification of nonsmall cell lung cancer (NSCLC) is evolving.
  • Lung adenocarcinoma is morphologically heterogeneous, with mixtures of acinar, papillary, bronchioloalveolar, and solid patterns in more than 80% of cases.
  • Adenocarcinoma was found in 32 (76%) of the 42 tumors.
  • We found that comparing adenocarcinomas is a complex issue that requires assessment not only of percentages of the histologic subtypes, but also the recording of additional histologic details such as cytologic features, patterns of stroma, necrosis, discrete nodularity versus miliary growth and variants such as clear cell, signet ring, mucinous, and fetal patterns.
  • We also found that paired squamous cell carcinomas could be compared based on histologic subtyping in addition to cytologic and stromal characteristics.
  • In summary, based on a well characterized cohort with detailed clinical, pathologic and molecular data, we found comprehensive histologic assessment is a powerful tool that seems to be a promising way to determine whether multiple lung adenocarcinomas or squamous cell carcinomas are metastatic or multiple primaries.
  • This has great clinical implications for staging and therapeutic management of lung cancer patients with multiple tumors.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / pathology. Carcinoma, Squamous Cell / pathology. Lung Neoplasms / pathology. Neoplasms, Multiple Primary

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2008 Jun;32(6):810-27 [18391747.001]
  • [Cites] Ann Thorac Surg. 2003 Oct;76(4):1001-7; discussion 1007-8 [14529975.001]
  • [Cites] J Thorac Cardiovasc Surg. 1975 Oct;70(4):606-12 [170482.001]
  • [Cites] J Thorac Oncol. 2008 Jan;3(1):13-7 [18166835.001]
  • [Cites] Cancer. 1995 Jan 1;75(1 Suppl):191-202 [8000996.001]
  • [Cites] Eur J Cardiothorac Surg. 2008 Aug;34(2):438-43; discussion 443 [18502660.001]
  • [Cites] Stat Med. 2010 Jul 10;29(15):1608-21 [20205270.001]
  • [Cites] Head Neck. 2002 Feb;24(2):198-206 [11891950.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Sep 7;101(36):13306-11 [15329413.001]
  • [Cites] J Clin Pathol. 2003 Jul;56(7):522-7 [12835298.001]
  • [Cites] Nature. 2008 Oct 23;455(7216):1069-75 [18948947.001]
  • [Cites] Clin Cancer Res. 2009 Aug 15;15(16):5184-90 [19671847.001]
  • [Cites] Clin Lung Cancer. 2007 Nov;8(9):562-4 [18186961.001]
  • [Cites] Respirology. 2006 Sep;11(5):533-8 [16916324.001]
  • [Cites] Nature. 2007 Dec 6;450(7171):893-8 [17982442.001]
  • [Cites] Am J Surg Pathol. 2003 Jan;27(1):101-9 [12502932.001]
  • [Cites] Eur Respir J. 2008 Apr;31(4):854-9 [18094005.001]
  • [Cites] Ann Thorac Surg. 2008 Sep;86(3):921-6 [18721583.001]
  • [Cites] J Thorac Cardiovasc Surg. 2007 May;133(5):1193-200 [17467428.001]
  • (PMID = 19773638.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA008748; United States / NCI NIH HHS / CA / R01 CA124504; United States / NCI NIH HHS / CA / CA124504
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


12. Safranek J, Pesta M, Holubec L, Kulda V, Dreslerova J, Vrzalova J, Topolcan O, Pesek M, Finek J, Treska V: Expression of MMP-7, MMP-9, TIMP-1 and TIMP-2 mRNA in lung tissue of patients with non-small cell lung cancer (NSCLC) and benign pulmonary disease. Anticancer Res; 2009 Jul;29(7):2513-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of MMP-7, MMP-9, TIMP-1 and TIMP-2 mRNA in lung tissue of patients with non-small cell lung cancer (NSCLC) and benign pulmonary disease.
  • The expression of matrix metallo-proteinases (MMP-7 and MMP-9) and tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2), which are involved in the degradation of the extracellular matrix (ECM) and tumor growth, was investigated in normal lung tissue, tissue of benign pulmonary diseases and non-small cell lung cancer (NSCLC) tissue.
  • PATIENTS AND METHODS: Tumor tissue and surrounding carcinoma-free lung tissue samples were obtained from 91 patients with NSCLC who had undergone surgery in the years 2005-2007 as well as lung tissue from 12 patients operated on for 'benign' bullous emphysema or interstitial lung disease.
  • RESULTS: Significantly higher expression of MMP-7, MMP-9 and TIMP-1 mRNA was demonstrated in the NSCLC tissue in comparison with the normal lung tissue from the same patients (p=0.0003, p<0.0001 and p=0.0018, respectively).
  • Similar results for MMP-7, MMP-9 and TIMP-1 were found in the histological subgroups: squamous cell lung cancer vs. normal tissue (p=0.0198, p=0.0015 and p=0.0366, respectively), and adenocarcinoma vs. normal tissue (p=0.0045, p<0.0001 and p=0.0140, respectively).
  • The expression of MMP-7 was found to be significantly higher in tumor tissue vs. lung tissue of the benign diseases (p=0.0086) and similar results were also recorded in the histological subgroups: squamous cell lung cancer vs. benign tissue (p=0.0171) and adenocarcinoma vs. benign tissue (p=0.0135).
  • The expression of MMP-9 was significantly higher only in the adenocarcinoma subgroup vs. the benign tissue (p=0.0412).
  • CONCLUSION: Significantly higher expression of MMP-7 and MMP-9 in tumor tissue than in the surrounding tissue or in benign lung disease tissue supports the notion of an important role of these metalloproteinases in the growth of lung carcinoma.
  • TIMP-1 expression is increased only in carcinoma, but not in benign lung disease.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / metabolism. Lung Diseases / metabolism. Lung Neoplasms / metabolism. Matrix Metalloproteinase 7 / genetics. Matrix Metalloproteinase 9 / genetics. Tissue Inhibitor of Metalloproteinase-1 / genetics. Tissue Inhibitor of Metalloproteinase-2 / genetics


13. Tokiwa H, Sera N, Nakanishi Y: Involvement of alveolar macrophages in the formation of 8-oxodeoxyguanosine associated with exogenous particles in human lungs. Inhal Toxicol; 2005 Oct;17(11):577-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Lung specimens were collected from 161 non-smoking male patients with carcinoma to determine the deposition of carbon particles and oxidative damage in lung tissues.
  • Morphologically, carbon particles deposited in human lungs with carcinoma were similar to those of diesel exhaust like particles, and mass of particles showed a significant increase with the increasing age of the patients.
  • To determine whether particles in lung tissues were associated with 8-oxo-dG formation, carbon particles deposited in lung tissues were partially purified by cycling of alkali fusion with 1 M KOH; mutagenic chemicals in particles were extracted and excluded by removal with an equal volume of benzene/methanol and dichloromethane.
  • These observations suggest that small particles from lung cancer patients further promote oxidative damage when used to treat the mouse lung.
  • [MeSH-major] Carbon / administration & dosage. Deoxyguanosine / analogs & derivatives. Lung / metabolism. Macrophages, Alveolar / metabolism
  • [MeSH-minor] Adenocarcinoma / metabolism. Adolescent. Adult. Age Factors. Aged. Aged, 80 and over. Animals. Cell Line. Child. Dose-Response Relationship, Drug. Female. Humans. Lung Neoplasms / metabolism. Male. Mice. Mice, Inbred BALB C. Mice, Inbred ICR. Microscopy, Electron, Scanning. Middle Aged. Monocytes / drug effects. Monocytes / metabolism. Particle Size. Pyrenes / chemistry. Pyrenes / metabolism

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. 1-NITROPYRENE .
  • Hazardous Substances Data Bank. CARBON .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16033753.001).
  • [ISSN] 0895-8378
  • [Journal-full-title] Inhalation toxicology
  • [ISO-abbreviation] Inhal Toxicol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Pyrenes; 5522-43-0 / 1-nitropyrene; 7440-44-0 / Carbon; 88847-89-6 / 8-oxo-7-hydrodeoxyguanosine; G9481N71RO / Deoxyguanosine
  •  go-up   go-down


14. Zell JA, Ou SH, Ziogas A, Anton-Culver H: Survival improvements for advanced stage nonbronchioloalveolar carcinoma-type nonsmall cell lung cancer cases with ipsilateral intrapulmonary nodules. Cancer; 2008 Jan 1;112(1):136-43
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival improvements for advanced stage nonbronchioloalveolar carcinoma-type nonsmall cell lung cancer cases with ipsilateral intrapulmonary nodules.
  • BACKGROUND: Survival improvements have been demonstrated for patients with bronchioloalveolar (BAC) nonsmall cell lung cancer (NSCLC) with intrapulmonary satellite T4 nodules compared with other patients with stage IIIB disease, and for ipsilateral intrapulmonary M1 tumors versus contralateral or distant metastasis.
  • Overall survival (OS) and lung cancer-specific survival (LCSS) univariate analyses were conducted using the Kaplan-Meier method.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / mortality. Lung Neoplasms / mortality
  • [MeSH-minor] Adenocarcinoma, Bronchiolo-Alveolar / mortality. Aged. Cause of Death. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Survival Analysis

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2007 American Cancer Society
  • (PMID = 17960795.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


15. Okasaka T, Matsuo K, Suzuki T, Ito H, Hosono S, Kawase T, Watanabe M, Yatabe Y, Hida T, Mitsudomi T, Tanaka H, Yokoi K, Tajima K: hOGG1 Ser326Cys polymorphism and risk of lung cancer by histological type. J Hum Genet; 2009 Dec;54(12):739-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] hOGG1 Ser326Cys polymorphism and risk of lung cancer by histological type.
  • Although several studies have investigated the association between rs1052133 and lung cancer susceptibility, the effect of this locus on lung cancer according to histology remains unclear.
  • We therefore conducted a case-control study with 515 incident lung cancer cases and 1030 age- and sex-matched controls without cancer, and further conducted a meta-analysis.
  • In overall analysis, the homozygous Cys/Cys genotype showed a significant association with lung cancer compared to Ser allele carrier status (odds ratio (OR)=1.31, 95% confidence interval (CI)=1.02-1.69).
  • By histology-based analysis, the Cys/Cys genotype showed a significantly positive association with small-cell carcinoma (OR=2.40, 95% CI=1.32-4.49) and marginally significant association with adenocarcinoma (OR=1.32, 95% CI=0.98-1.77).
  • A meta-analysis of previous and our present study revealed that this polymorphism is positively associated with adenocarcinoma, although suggestive associations were also found for squamous- and small-cell lung cancers.
  • These results indicate that rs1052133 contributes to the risk of adenocarcinoma of lung.
  • [MeSH-major] Adenocarcinoma / genetics. Carcinoma, Small Cell / genetics. Carcinoma, Squamous Cell / genetics. DNA Glycosylases / genetics. Lung Neoplasms / genetics. Polymorphism, Single Nucleotide

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CYSTEINE .
  • Hazardous Substances Data Bank. L-SERINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • Nature Publishing Group. Nature Publishing Group (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19881468.001).
  • [ISSN] 1435-232X
  • [Journal-full-title] Journal of human genetics
  • [ISO-abbreviation] J. Hum. Genet.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 452VLY9402 / Serine; EC 3.2.2.- / DNA Glycosylases; EC 3.2.2.- / oxoguanine glycosylase 1, human; K848JZ4886 / Cysteine
  •  go-up   go-down


16. Al-Kuraya K, Siraj AK, Bavi P, Al-Jommah N, Ezzat A, Sheikh S, Amr S, Al-Dayel F, Simon R, Guido S: High epidermal growth factor receptor amplification rate but low mutation frequency in Middle East lung cancer population. Hum Pathol; 2006 Apr;37(4):453-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High epidermal growth factor receptor amplification rate but low mutation frequency in Middle East lung cancer population.
  • Epidermal growth factor receptor (EGFR) exon 18-21 mutations were shown to be highly predictive of response to gefitinib (Iressa) therapy in lung cancer.
  • Studies on Western and Japanese lung cancers have indicated substantial differences in the EGFR mutation frequency between these populations.
  • To investigate the prevalence of EGFR in another distinct ethnic group, EGFR alterations were studied in 47 consecutive non small cell lung cancers from Saudi Arabia by immunohistochemistry, fluorescence in situ hybridization, and DNA sequencing.
  • Only 1 exon 18-21 mutation was seen among 34 lung cancers that could be successfully sequenced.
  • It is concluded that EGFR exon 18-21 mutations are rare in Middle East patients with lung cancer and occur in a similar range as in Western patients.
  • [MeSH-major] Adenocarcinoma / genetics. Carcinoma, Squamous Cell / genetics. Gene Amplification. Lung Neoplasms / genetics. Mutation. Receptor, Epidermal Growth Factor / genetics

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16564920.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / DNA, Neoplasm; 0 / Quinazolines; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; S65743JHBS / gefitinib
  •  go-up   go-down


17. Fujiwara Y, Kiura K, Toyooka S, Takigawa N, Tokumo M, Hotta K, Aoe M, Tabata M, Matsuo K, Date H, Tanimoto M: Relationship between epidermal growth factor receptor gene mutations and the severity of adverse events by gefitinib in patients with advanced non-small cell lung cancer. Lung Cancer; 2006 Apr;52(1):99-103
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relationship between epidermal growth factor receptor gene mutations and the severity of adverse events by gefitinib in patients with advanced non-small cell lung cancer.
  • PURPOSE: Recent reports have demonstrated that mutation of epidermal growth factor receptor (EGFR) gene is predictive factor for tumor responsiveness to gefitinib suggesting the importance of EGFR status for the treatment of the patients with non-small cell lung cancer (NSCLC).
  • EGFR mutation status was correlated with neither its frequency nor severity of adverse events during gefitinib treatment including skin rash, diarrhea, liver injury, and interstitial lung disease.
  • [MeSH-major] Adenocarcinoma / genetics. Antineoplastic Agents / adverse effects. Carcinoma, Non-Small-Cell Lung / genetics. Lung Neoplasms / genetics. Mutation / genetics. Quinazolines / adverse effects. Receptor, Epidermal Growth Factor / genetics


18. El Ouazzani H, Menchafou I, Achachi L, El Ftouh M, El Fassy Fihry MT: [Delay in the diagnosis of primary bronchial cancer. Study carried out in the pneumology unit of Ibn Sina university hospital, Rabat (Morocco)]. Rev Pneumol Clin; 2010 Dec;66(6):335-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The time before treatment was shorter for small cell carcinomas (SCC) (23 days vs. 31 days: p: 0.06).
  • [MeSH-major] Carcinoma, Bronchogenic / diagnosis. Developing Countries. Lung Neoplasms / diagnosis
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / epidemiology. Adenocarcinoma / pathology. Adenocarcinoma / therapy. Adult. Aged. Aged, 80 and over. Carcinoma, Large Cell / diagnosis. Carcinoma, Large Cell / epidemiology. Carcinoma, Large Cell / pathology. Carcinoma, Large Cell / therapy. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / therapy. Female. Health Services Accessibility / statistics & numerical data. Hospitals, University. Humans. Male. Middle Aged. Morocco. Neoplasm Staging. Patient Admission / statistics & numerical data. Smoking / adverse effects. Smoking / pathology. Socioeconomic Factors. Uncompensated Care / statistics & numerical data

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Masson SAS. All rights reserved.
  • (PMID = 21167440.001).
  • [ISSN] 0761-8417
  • [Journal-full-title] Revue de pneumologie clinique
  • [ISO-abbreviation] Rev Pneumol Clin
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


19. Imaizumi M, Study Group of Adjuvant Chemotherapy for Lung Cancer (Chubu, Japan): Postoperative adjuvant cisplatin, vindesine, plus uracil-tegafur chemotherapy increased survival of patients with completely resected p-stage I non-small cell lung cancer. Lung Cancer; 2005 Jul;49(1):85-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Postoperative adjuvant cisplatin, vindesine, plus uracil-tegafur chemotherapy increased survival of patients with completely resected p-stage I non-small cell lung cancer.
  • PURPOSE: To evaluate the efficacy of postoperative adjuvant chemotherapy for completely resected p-stage I non-small cell lung cancer (NSCLC).
  • MATERIALS AND METHODS: Patients who underwent complete resection with lymph node dissection for p-stage I NSCLC (T1N0, T2N0, adenocarcinoma or squamous cell carcinoma, were eligible.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / surgery. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / surgery. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / surgery. Lung Neoplasms / drug therapy. Lung Neoplasms / surgery

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. VINDESINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15949594.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial
  • [Publication-country] Ireland
  • [Chemical-registry-number] 1548R74NSZ / Tegafur; Q20Q21Q62J / Cisplatin; RSA8KO39WH / Vindesine
  •  go-up   go-down


20. Gurpide A, Perez-Gracia JL, Lopez-Picazo JM, Moreno M, Zubieta JL, Martin-Algarra S, Garcia-Foncillas J: Activity of gefitinib in central nervous system metastases in patients with non-small-cell lung cancer: two case reports and a review of the literature. Clin Lung Cancer; 2005 Sep;7(2):138-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Activity of gefitinib in central nervous system metastases in patients with non-small-cell lung cancer: two case reports and a review of the literature.
  • Gefitinib is the first inhibitor of the epidermal growth factor receptor that has shown activity in non-small-cell lung cancer (NSCLC), but its potential value in the treatment of central nervous system (CNS) metastases has been rarely assessed.
  • Responses have been most frequently observed in female patients with adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Central Nervous System Neoplasms / drug therapy. Lung Neoplasms / drug therapy. Quinazolines / therapeutic use


21. Cassidy A, 't Mannetje A, van Tongeren M, Field JK, Zaridze D, Szeszenia-Dabrowska N, Rudnai P, Lissowska J, Fabianova E, Mates D, Bencko V, Foretova L, Janout V, Fevotte J, Fletcher T, Brennan P, Boffetta P: Occupational exposure to crystalline silica and risk of lung cancer: a multicenter case-control study in Europe. Epidemiology; 2007 Jan;18(1):36-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Occupational exposure to crystalline silica and risk of lung cancer: a multicenter case-control study in Europe.
  • BACKGROUND: The role of crystalline silica dust as a possible cause of lung cancer has been controversial.
  • Relatively few large community-based studies have been conducted to investigate the lung cancer risk from exposure to silica at low levels, taking into account potential confounding factors.
  • METHODS: Detailed lifestyle and occupational information were collected from 2852 newly diagnosed cases of lung cancer and 3104 controls between 1998 and 2002 in 7 European countries.
  • RESULTS: Occupational exposure to crystalline silica was associated with an increased risk of lung cancer (odds ratio = 1.37; 95% confidence interval = 1.14-1.65).
  • CONCLUSIONS: Our results support the hypothesis that silica is an important risk factor for lung cancer.
  • This risk could not be explained by exposure to other occupational carcinogens or smoking, and it was present for the main histologic types of lung cancer, different sources of silica exposure, and different industrial settings.
  • [MeSH-major] Adenocarcinoma / epidemiology. Air Pollutants, Occupational / adverse effects. Carcinoma, Small Cell / epidemiology. Carcinoma, Squamous Cell / epidemiology. Lung Neoplasms / epidemiology. Occupational Exposure / adverse effects. Silicon Dioxide / adverse effects

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Occupational Health.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Epidemiology. 2007 Jan;18(1):23-4 [17179757.001]
  • (PMID = 17149143.001).
  • [ISSN] 1044-3983
  • [Journal-full-title] Epidemiology (Cambridge, Mass.)
  • [ISO-abbreviation] Epidemiology
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G9900432
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Air Pollutants, Occupational; 7631-86-9 / Silicon Dioxide
  •  go-up   go-down


22. Mylonakis N, Athanasiou A, Ziras N, Angel J, Rapti A, Lampaki S, Politis N, Karanikas C, Kosmas C: Phase II study of liposomal cisplatin (Lipoplatin) plus gemcitabine versus cisplatin plus gemcitabine as first line treatment in inoperable (stage IIIB/IV) non-small cell lung cancer. Lung Cancer; 2010 May;68(2):240-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of liposomal cisplatin (Lipoplatin) plus gemcitabine versus cisplatin plus gemcitabine as first line treatment in inoperable (stage IIIB/IV) non-small cell lung cancer.
  • A preliminary efficacy of LipoGem versus CisGem in the adenocarcinoma histological subtype of NSCLC showed 16.7% versus 45.8% PD.
  • CONCLUSION: Overall, Lipoplatin appears to have lower toxicity, mainly renal toxicity as well as higher efficacy than cisplatin when combined with gemcitabine in advanced NSCLC.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Cisplatin / administration & dosage. Lung Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 19628292.001).
  • [ISSN] 1872-8332
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / lipoplatin; 0W860991D6 / Deoxycytidine; AYI8EX34EU / Creatinine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


23. Monica V, Ceppi P, Righi L, Tavaglione V, Volante M, Pelosi G, Scagliotti GV, Papotti M: Desmocollin-3: a new marker of squamous differentiation in undifferentiated large-cell carcinoma of the lung. Mod Pathol; 2009 May;22(5):709-17
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Desmocollin-3: a new marker of squamous differentiation in undifferentiated large-cell carcinoma of the lung.
  • Lung cancer classification in small-cell and non-small-cell types was recently challenged by data on the differential efficacy of new cytotoxic agents in specific histotypes.
  • An accurate histotype definition has therefore gained interest in both preoperative and surgical materials, but is a hard task especially in undifferentiated large-cell tumors lacking morphological signs of squamous or glandular differentiation.
  • On the basis of gene expression profiling data, reporting a remarkable differential expression of desmocollin-3 (a protein localized in desmosomal junctions of stratified epithelial) between adeno- and squamous cancers, we immunostained 62 cases of resected undifferentiated large-cell lung carcinomas for desmocollin-3 (and for TTF-1, p63 and mucin stain), to test its ability to identify a (residual) squamous phenotype, if present.
  • Desmocollin-3 was expressed in almost half of the undifferentiated large-cell cancers and was mutually exclusive with TTF-1 (positive in 39%; the remaining 18 % of cases was double negative).
  • Special large-cell carcinoma variants expressed desmocollin-3 in 6 of 6 basaloid, 7 of 12 clear-cell types, again mutually exclusive with TTF-1 expression.
  • In 31 cytological samples diagnosed as 'non-small-cell lung carcinoma', desmocollin-3 was again mutually exclusive with TTF-1 and stained all squamous carcinomas, 1 of 19 adenocarcinoma only, and 50% of large-cell carcinoma (all histologically confirmed).
  • This combined morphophenotypic approach may represent a valid adjunct (for both surgical and cytological samples) in the selection of patients with lung cancer to medical treatments tailored according to different efficacy in different lung carcinomas of the squamous, adeno- and large-cell types.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Large Cell / pathology. Carcinoma, Squamous Cell / pathology. Desmocollins / biosynthesis. Lung Neoplasms / pathology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19287461.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / DSC3 protein, human; 0 / Desmocollins; 0 / TTF1 protein, human
  •  go-up   go-down


24. Büchel GE, Stepanenko IN, Hejl M, Jakupec MA, Arion VB, Keppler BK: [Os(IV)Cl(5)(Hazole)](-) complexes: synthesis, structure, spectroscopic properties, and antiproliferative activity. Inorg Chem; 2009 Nov 16;48(22):10737-47
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Compounds 6-11 were found to possess modest antiproliferative acitivity in vitro against CH1 (ovarian carcinoma), A549 (non-small cell lung carcinoma), and SW480 (colon adenocarcinoma) cells with IC(50) values in the 10(-4) M concentration range.
  • [MeSH-minor] Cell Line, Tumor. Cell Proliferation / drug effects. Crystallography, X-Ray. Electrochemistry. Humans. Hydrolysis. Indazoles / chemistry. Magnetic Resonance Spectroscopy. Magnetics. Solubility. Water / chemistry

  • Hazardous Substances Data Bank. OSMIUM, ELEMENTAL .
  • Hazardous Substances Data Bank. Water .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19842663.001).
  • [ISSN] 1520-510X
  • [Journal-full-title] Inorganic chemistry
  • [ISO-abbreviation] Inorg Chem
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Indazoles; 0 / Organometallic Compounds; 0 / Pyrazoles; 059QF0KO0R / Water; 2E7M255OPY / Osmium; 3QD5KJZ7ZJ / pyrazole
  •  go-up   go-down


25. Dai L, Fang J, Nie J, Hu W, Chen X, Han J, Tian G, Han S, Liu X: [Analysis of prognostic factors of 80 advanced NSCLC patients treated with gefitinib for more than 6 months]. Zhongguo Fei Ai Za Zhi; 2010 Nov;13(11):1050-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Some clinical predictors can be used to evaluate the efficacy of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy for non-small cell lung cancer (NSCLC), including female, East-Asian, non-smoker, adenocarcinoma, skin rash, etc.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Quinazolines / therapeutic use

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21081047.001).
  • [ISSN] 1999-6187
  • [Journal-full-title] Zhongguo fei ai za zhi = Chinese journal of lung cancer
  • [ISO-abbreviation] Zhongguo Fei Ai Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Quinazolines; S65743JHBS / gefitinib
  •  go-up   go-down


26. Xu AH, Yin YW, Chen FH: [The value of serum endostatin level in early diagnosis of lung cancer]. Zhonghua Yi Xue Za Zhi; 2006 Jul 18;86(27):1916-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The value of serum endostatin level in early diagnosis of lung cancer].
  • OBJECTIVE: To investigate value of serum endostatin level in early diagnosis of lung cancer.
  • METHODS: ELISA was used to detect the level of serum endostatin at in 40 lung carcinoma patients, 18 males and 4 females, aged 59.50 +/- 14.58.
  • The serum endostatin levels of the lung cancer patients at different clinical stage and of different pathological types were analyzed.
  • Twenty patients with benign lung disease and 20 normal persons were used as controls. RESULTS:.
  • (1) The serum endostatin level of the lung cancer patients was 10.71 +/- 9.99) ng/ml, significantly higher than those of the patients with benign lung diseases and the normal persons (4.79 +/- 1.23 ng/ml and 4.51 +/- 1.14 ng/ml, respectively, both P < 0.01). (2) The serum endostatin level of the lung cancer patients at the stage I and II were 13.63 +/- 13.13 ng/ml and 12.35 +/- 5.79 ng/ml respectively, booth significantly higher than that of the patients at the stage III (6.29 +/- 1.64, P = 0.023 and P = 0.023). (3) There were no significant differences in the serum endostatin level among the lung cancer patients with different pathological types. (4) The serum endostatin level of the lung cancer patients after chemotherapy was 7.83 +/- 1.48 ng/ml, significantly higher than that before the chemotherapy (5.59 +/- 1.74, P = 0.04).
  • CONCLUSION:. (1) Rising in lung cancer at stages I and II, level of serum may probably be used as the a sign in early diagnosis of lung cancer. (2) After chemotherapy the level of endostatin has a trend of rising.
  • [MeSH-major] Endostatins / blood. Lung Neoplasms / diagnosis
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Aged. Carcinoma, Small Cell / diagnosis. Carcinoma, Small Cell / pathology. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / pathology. Early Diagnosis. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Serologic Tests

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17064531.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Endostatins
  •  go-up   go-down


27. Guo JT, Ding LH, Liang CY, Zhou NK, Ye QN: [Expression of EYA2 in non-small cell lang cancer]. Zhonghua Zhong Liu Za Zhi; 2009 Jul;31(7):528-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of EYA2 in non-small cell lang cancer].
  • OBJECTIVE: To identify the expression of Drosophila Eyes Absent Homologue 2 (EYA2) in non-small cell lung cancer (NSCLC) and to investigate its correlation with clinical parameters.
  • METHODS: 59 fresh specimens of lung cancer and paired normal lung tissue were obtained from 59 NSCLC cases treated in the department of thoracic surgery in our hospital from June 2006 to October 2007.
  • EYA2 expression was significantly up-regulated in adenocarcinoma, while not changed in lung squamous cell carcinoma.
  • CONCLUSION: The results of this study suggest that expression of EYA2 in lung adenocarcinoma is augmented.
  • EYA2 is likely participating in the development of lung adenocarcinoma as a transcriptional activator.
  • [MeSH-major] Adenocarcinoma / metabolism. Carcinoma, Non-Small-Cell Lung / metabolism. Carcinoma, Squamous Cell / metabolism. Intracellular Signaling Peptides and Proteins / metabolism. Lung Neoplasms / metabolism. Nuclear Proteins / metabolism. Protein Tyrosine Phosphatases / metabolism
  • [MeSH-minor] Adult. Aged. Cytoplasm / metabolism. Female. Humans. Lung / metabolism. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Up-Regulation

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19950702.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Intracellular Signaling Peptides and Proteins; 0 / Nuclear Proteins; EC 3.1.3.48 / EYA2 protein, human; EC 3.1.3.48 / Protein Tyrosine Phosphatases
  •  go-up   go-down


28. Grills IS, Fitch DL, Goldstein NS, Yan D, Chmielewski GW, Welsh RJ, Kestin LL: Clinicopathologic analysis of microscopic extension in lung adenocarcinoma: defining clinical target volume for radiotherapy. Int J Radiat Oncol Biol Phys; 2007 Oct 1;69(2):334-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic analysis of microscopic extension in lung adenocarcinoma: defining clinical target volume for radiotherapy.
  • PURPOSE: To determine the gross tumor volume (GTV) to clinical target volume margin for non-small-cell lung cancer treatment planning.
  • METHODS: A total of 35 patients with Stage T1N0 adenocarcinoma underwent wedge resection plus immediate lobectomy.
  • The gross tumor dimensions were measured on a computed tomography (CT) scan (lung and mediastinal windows) and compared with the pathologic dimensions.
  • The potential coverage of microscopic extension for two different lung stereotactic radiotherapy regimens was evaluated.
  • The CT lung windows correlated better with the pathologic size than did the mediastinal windows (gross pathologic size overestimated by a mean of 5.8 mm; composite size [gross plus microscopic extension] underestimated by a mean of 1.2 mm).
  • For a GTV contoured on the CT lung windows, the margin required to cover microscopic extension for 90% of the cases would be 9 mm (9, 7, and 4 mm for Grade 1 to 3, respectively).
  • CONCLUSION: For lung adenocarcinomas, the GTV should be contoured using CT lung windows.
  • Although a GTV based on the CT lung windows would underestimate the gross tumor size plus microscopic extension by only 1.2 mm for the average case, the clinical target volume expansion required to cover the microscopic extension in 90% of cases could be as large as 9 mm, although considerably smaller for high-grade tumors.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / pathology. Carcinoma, Non-Small-Cell Lung / radiography. Lung Neoplasms / pathology. Lung Neoplasms / radiography. Tumor Burden
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / radiography. Adenocarcinoma / radiotherapy. Adenocarcinoma / surgery. Humans. Radiosurgery. Radiotherapy Dosage. Radiotherapy Planning, Computer-Assisted

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17570609.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


29. West HL, Franklin WA, McCoy J, Gumerlock PH, Vance R, Lau DH, Chansky K, Crowley JJ, Gandara DR: Gefitinib therapy in advanced bronchioloalveolar carcinoma: Southwest Oncology Group Study S0126. J Clin Oncol; 2006 Apr 20;24(12):1807-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gefitinib therapy in advanced bronchioloalveolar carcinoma: Southwest Oncology Group Study S0126.
  • PURPOSE: Advanced bronchioloalveolar carcinoma (BAC) is a distinct subtype of non-small-cell lung cancer (NSCLC) for which there is currently no optimal therapy.
  • Toxicity consisted mainly of rash and diarrhea, but 2% of patients died of presumed interstitial lung disease.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / drug therapy. Antineoplastic Agents / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Quinazolines / therapeutic use

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16622257.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA11083; United States / NCI NIH HHS / CA / CA12644; United States / NCI NIH HHS / CA / CA14028; United States / NCI NIH HHS / CA / CA16385; United States / NCI NIH HHS / CA / CA20319; United States / NCI NIH HHS / CA / CA22433; United States / NCI NIH HHS / CA / CA32102; United States / NCI NIH HHS / CA / CA35090; United States / NCI NIH HHS / CA / CA35119; United States / NCI NIH HHS / CA / CA35176; United States / NCI NIH HHS / CA / CA35178; United States / NCI NIH HHS / CA / CA35261; United States / NCI NIH HHS / CA / CA35431; United States / NCI NIH HHS / CA / CA37981; United States / NCI NIH HHS / CA / CA38926; United States / NCI NIH HHS / CA / CA42777; United States / NCI NIH HHS / CA / CA45377; United States / NCI NIH HHS / CA / CA45450; United States / NCI NIH HHS / CA / CA45560; United States / NCI NIH HHS / CA / CA45808; United States / NCI NIH HHS / CA / CA46282; United States / NCI NIH HHS / CA / CA46368; United States / NCI NIH HHS / CA / CA46441; United States / NCI NIH HHS / CA / CA58416; United States / NCI NIH HHS / CA / CA58861; United States / NCI NIH HHS / CA / CA58882; United States / NCI NIH HHS / CA / CA63844; United States / NCI NIH HHS / CA / CA63848; United States / NCI NIH HHS / CA / CA67575; United States / NCI NIH HHS / CA / CA67663; United States / NCI NIH HHS / CA / CA74547; United States / NCI NIH HHS / CA / CA76448; United States / NCI NIH HHS / CA / CA86780
  • [Publication-type] Clinical Trial; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Quinazolines; S65743JHBS / gefitinib
  •  go-up   go-down


30. Davies H, Hunter C, Smith R, Stephens P, Greenman C, Bignell G, Teague J, Butler A, Edkins S, Stevens C, Parker A, O'Meara S, Avis T, Barthorpe S, Brackenbury L, Buck G, Clements J, Cole J, Dicks E, Edwards K, Forbes S, Gorton M, Gray K, Halliday K, Harrison R, Hills K, Hinton J, Jones D, Kosmidou V, Laman R, Lugg R, Menzies A, Perry J, Petty R, Raine K, Shepherd R, Small A, Solomon H, Stephens Y, Tofts C, Varian J, Webb A, West S, Widaa S, Yates A, Brasseur F, Cooper CS, Flanagan AM, Green A, Knowles M, Leung SY, Looijenga LH, Malkowicz B, Pierotti MA, Teh BT, Yuen ST, Lakhani SR, Easton DF, Weber BL, Goldstraw P, Nicholson AG, Wooster R, Stratton MR, Futreal PA: Somatic mutations of the protein kinase gene family in human lung cancer. Cancer Res; 2005 Sep 1;65(17):7591-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Somatic mutations of the protein kinase gene family in human lung cancer.
  • We screened the coding sequences of 518 protein kinases (approximately 1.3 Mb of DNA per sample) for somatic mutations in 26 primary lung neoplasms and seven lung cancer cell lines.
  • There was considerable variation between individual lung cancers in the number of mutations observed and no mutations were found in lung carcinoids.
  • The mutational spectra of most lung cancers were characterized by a high proportion of C:G > A:T transversions, compatible with the mutagenic effects of tobacco carcinogens.
  • However, one neuroendocrine cancer cell line had a distinctive mutational spectrum reminiscent of UV-induced DNA damage.
  • The results suggest that several mutated protein kinases may be contributing to lung cancer development, but that mutations in each one are infrequent.
  • [MeSH-major] Lung Neoplasms / enzymology. Lung Neoplasms / genetics. Mutation. Protein Kinases / genetics
  • [MeSH-minor] Adenocarcinoma / enzymology. Adenocarcinoma / genetics. Carcinoid Tumor / enzymology. Carcinoid Tumor / genetics. Carcinoma, Large Cell / enzymology. Carcinoma, Large Cell / genetics. Carcinoma, Squamous Cell / enzymology. Carcinoma, Squamous Cell / genetics. Cell Line, Tumor. DNA Mutational Analysis. Humans

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16140923.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United Kingdom / Wellcome Trust / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.- / Protein Kinases
  •  go-up   go-down


31. Taron M, Ichinose Y, Rosell R, Mok T, Massuti B, Zamora L, Mate JL, Manegold C, Ono M, Queralt C, Jahan T, Sanchez JJ, Sanchez-Ronco M, Hsue V, Jablons D, Sanchez JM, Moran T: Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas. Clin Cancer Res; 2005 Aug 15;11(16):5878-85
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas.
  • EXPERIMENTAL DESIGN: We examined EGFR mutations at exons 18, 19, and 21 in tumor tissue from 68 gefitinib-treated, chemorefractory, advanced non-small cell lung cancer patients from the United States, Europe, and Asia and in a highly gefitinib-sensitive non-small cell lung cancer cell line and correlated their presence with response and survival.
  • RESULTS: Seventeen patients had EGFR mutations, all of which were in lung adenocarcinomas.
  • CONCLUSIONS: The presence of EGFR mutations is a major determinant of gefitinib response, and targeting EGFR should be considered in preference to chemotherapy as first-line treatment in lung adenocarcinomas that have demonstrable EGFR mutations.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Pharmacogenomics Knowledge Base. meta-databases - Pharmacogenomic Annotation 981419812 for PMID:16115929 [PharmGKB] .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Clin Cancer Res. 2005 Aug 15;11(16):5668-70 [16115901.001]
  • (PMID = 16115929.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA093708-01A3; United States / NCI NIH HHS / CA / R01 CA093708; United States / NCI NIH HHS / CA / R01 CA093708-01A3
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Quinazolines; 0 / RNA, Messenger; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; S65743JHBS / gefitinib
  •  go-up   go-down


32. Kimura F, Kawamura J, Watanabe J, Kamoshida S, Kawai K, Okayasu I, Kuwao S: Significance of cell proliferation markers (Minichromosome maintenance protein 7, topoisomerase IIalpha and Ki-67) in cavital fluid cytology: can we differentiate reactive mesothelial cells from malignant cells? Diagn Cytopathol; 2010 Mar;38(3):161-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Significance of cell proliferation markers (Minichromosome maintenance protein 7, topoisomerase IIalpha and Ki-67) in cavital fluid cytology: can we differentiate reactive mesothelial cells from malignant cells?
  • MCM 7, topo IIalpha, and Ki-67 are different types of cell proliferation markers.
  • [MeSH-major] Antigens, Neoplasm / metabolism. Ascitic Fluid / pathology. Cell Cycle Proteins / metabolism. Cell Proliferation. DNA Topoisomerases, Type II / metabolism. DNA-Binding Proteins / metabolism. Ki-67 Antigen / metabolism. Nuclear Proteins / metabolism. Thoracic Cavity / pathology
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Aged. Biomarkers, Tumor / metabolism. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Epithelium / metabolism. Epithelium / pathology. Female. Humans. Immunoenzyme Techniques. Male. Mesothelioma / metabolism. Mesothelioma / pathology. Minichromosome Maintenance Complex Component 7. Peritoneal Neoplasms / metabolism. Peritoneal Neoplasms / pathology. Pleural Neoplasms / metabolism. Pleural Neoplasms / pathology. Small Cell Lung Carcinoma / metabolism. Small Cell Lung Carcinoma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19821496.001).
  • [ISSN] 1097-0339
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Cell Cycle Proteins; 0 / DNA-Binding Proteins; 0 / Ki-67 Antigen; 0 / Nuclear Proteins; EC 3.6.4.12 / MCM7 protein, human; EC 3.6.4.12 / Minichromosome Maintenance Complex Component 7; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha
  •  go-up   go-down


33. Togashi K, Koike T, Emura I, Usuda H: [Indication for limited surgery on small lung cancer tumors measuring 1cm or less in diameter on preoperative computed tomography and long-term results]. Kyobu Geka; 2008 Jul;61(7):519-22; discussion 522-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Indication for limited surgery on small lung cancer tumors measuring 1cm or less in diameter on preoperative computed tomography and long-term results].
  • OBJECTIVE: Non-invasive lung cancers showed a good prognosis after limited surgery.
  • But it is still uncertain about invasive lung cancers.
  • We investigated the indications for limited surgery for small lung cancer tumors measuring 1 cm or less in diameter on preoperative computed tomography (CT).
  • METHODS: This study retrospectively analyzed of 1,245 patients who underwent complete resection of lung cancer between 1989 and 2004 in our hospital.
  • RESULTS: All diseases were detected by medical checkup, 52 % of the patients were not definitively diagnosed with lung cancer before surgery.
  • Adenocarcinoma was histologically diagnosed in 49 patients (79%).
  • Other histologic types included squamous cell carcinoma (8), large cell carcinoma (1), small cell carcinoma (1), carcinoid (2), and adenosquamous cell carcinoma (1).
  • There were 3 deaths from cancer recurrence, while there were no deaths in 14 patients with bronchioloalveolar carcinoma CONCLUSION: After limited surgery, non-invasive cancer showed good long-term results, while invasive cancer showed a recurrence rate of 2.3% to 79% even though the tumor measured 1 cm or less in diameter on preoperative CT.
  • [MeSH-major] Carcinoma, Small Cell / pathology. Carcinoma, Small Cell / surgery. Lung Neoplasms / pathology. Lung Neoplasms / surgery. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18616092.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


34. Kikuchi S, Yamada D, Fukami T, Maruyama T, Ito A, Asamura H, Matsuno Y, Onizuka M, Murakami Y: Hypermethylation of the TSLC1/IGSF4 promoter is associated with tobacco smoking and a poor prognosis in primary nonsmall cell lung carcinoma. Cancer; 2006 Apr 15;106(8):1751-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypermethylation of the TSLC1/IGSF4 promoter is associated with tobacco smoking and a poor prognosis in primary nonsmall cell lung carcinoma.
  • BACKGROUND: The tumor suppressor gene TSLC1/IGSF4 on chromosomal region 11q23 is frequently inactivated by promoter methylation in various cancers, including nonsmall cell lung carcinoma (NSCLC).
  • Methylation was observed in all histologic subtypes of NSCLC, including adenocarcinoma (29 of 68, 43%), squamous cell carcinoma (14 of 26, 54%), adenosquamous carcinoma (1 of 2, 50%), and large cell carcinoma (1 of 7, 14%).
  • The TSLC1/IGSF4 methylation was also significantly associated with a shorter disease-free survival (P = .049), providing an independent prognostic factor (P = .038) in adenocarcinoma patients.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / genetics. DNA Methylation. Genes, Tumor Suppressor. Immunoglobulins / genetics. Lung Neoplasms / genetics. Membrane Proteins / genetics. Promoter Regions, Genetic. Smoking / genetics. Tumor Suppressor Proteins / genetics
  • [MeSH-minor] Aged. Cell Adhesion Molecules. CpG Islands / genetics. Disease-Free Survival. Female. Humans. Male. Polymorphism, Single-Stranded Conformational. Prognosis

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Smoking.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2006 American Cancer Society
  • (PMID = 16534787.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CADM1 protein, human; 0 / Cell Adhesion Molecules; 0 / Immunoglobulins; 0 / Membrane Proteins; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


35. Alexandre J: [Proteasome inhibitors]. Rev Med Interne; 2005 Oct;26(10):812-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Proteasome is involved in cell cycle and apoptosis regulation.
  • As single agent, bortezomib displays antitumoral effects in refractory multiple myeloma and mantle cell lymphoma but has only modest activity in solid tumors.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16129520.001).
  • [ISSN] 0248-8663
  • [Journal-full-title] La Revue de medecine interne
  • [ISO-abbreviation] Rev Med Interne
  • [Language] FRE
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; 0 / Boronic Acids; 0 / Protease Inhibitors; 0 / Proteasome Inhibitors; 0 / Pyrazines; 0 / Taxoids; 15H5577CQD / docetaxel; 69G8BD63PP / Bortezomib; 7S5I7G3JQL / Dexamethasone
  •  go-up   go-down


36. Zemaitis M, Sakalauskas R, Malakauskas K, Muley T, Fischer JR, Lahm H: [Clinical and prognostic significance of tumor markers cytokeratin 19 fragment, carcinoembryonic antigen, and neuron-specific enolase in lung cancer]. Medicina (Kaunas); 2005;41(7):566-76
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical and prognostic significance of tumor markers cytokeratin 19 fragment, carcinoembryonic antigen, and neuron-specific enolase in lung cancer].
  • OBJECTIVE: To evaluate the clinical and prognostic significance of the tumor markers cytokeratin 19 fragment, carcinoembryonic antigen and neuron-specific enolase in lung cancer patients.
  • MATERIALS AND METHODS: Serum levels of cytokeratin 19 fragment, carcinoembryonic antigen and neuron-specific enolase were measured using electrochemical luminescence immunoassay in 46 lung cancer patients.
  • The number of patients with elevated levels of cytokeratin 19 fragment and neuron-specific enolase was higher in more advanced disease than in early lung cancer (p=0.036 and p=0.036, respectively).
  • Preoperative levels of cytokeratin 19 fragment (p=0.017 and p=0.016, respectively) and neuron-specific enolase (p=0.03 and p=0.006, respectively) were significantly associated with more advanced disease and tumor size, as well as tumor histology in non-small cell lung cancer (p=0.03 and p=0.016, respectively).
  • Preoperative levels of cytokeratin 19 fragments were higher in squamous cell carcinoma than in adenocarcinoma (p=0.026).
  • Elevated preoperative serum levels of cytokeratin 19 fragment predict a poor prognosis for lung cancer patients (p=0.007).
  • [MeSH-major] Adenocarcinoma / diagnosis. Carcinoembryonic Antigen / blood. Carcinoma, Non-Small-Cell Lung / diagnosis. Carcinoma, Squamous Cell / diagnosis. Keratins / blood. Lung Neoplasms / diagnosis. Phosphopyruvate Hydratase / blood
  • [MeSH-minor] Adult. Aged. Female. Humans. Lung / pathology. Male. Middle Aged. Neoplasm Staging. Prognosis. Smoking

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16062024.001).
  • [ISSN] 1648-9144
  • [Journal-full-title] Medicina (Kaunas, Lithuania)
  • [ISO-abbreviation] Medicina (Kaunas)
  • [Language] lit
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Lithuania
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen; 68238-35-7 / Keratins; EC 4.2.1.11 / Phosphopyruvate Hydratase
  •  go-up   go-down


37. Li J, Chen P, Dai CH, Li XQ, Bao QL: Prognostic factors in elderly patients with advanced non-small cell lung cancer treated with chemotherapy. Oncology; 2009;76(5):355-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors in elderly patients with advanced non-small cell lung cancer treated with chemotherapy.
  • OBJECTIVE: The prognosis of advanced non-small cell lung cancer (NSCLC) is poor.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Aged. Aged, 80 and over. Carcinoma, Large Cell / drug therapy. Carcinoma, Large Cell / secondary. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / secondary. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Disease Progression. Etoposide / administration & dosage. Female. Humans. Male. Medical Records. Neoplasm Staging. Paclitaxel / administration & dosage. Prognosis. Retrospective Studies. Survival Rate. Treatment Outcome. Vinblastine / administration & dosage. Vinblastine / analogs & derivatives

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. VINORELBINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • (PMID = 19321963.001).
  • [ISSN] 1423-0232
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 5V9KLZ54CY / Vinblastine; 6PLQ3CP4P3 / Etoposide; B76N6SBZ8R / gemcitabine; P88XT4IS4D / Paclitaxel; Q6C979R91Y / vinorelbine
  •  go-up   go-down


38. Hata M, Tokuuye K, Kagei K, Sugahara S, Nakayama H, Fukumitsu N, Hashimoto T, Mizumoto M, Ohara K, Akine Y: Hypofractionated high-dose proton beam therapy for stage I non-small-cell lung cancer: preliminary results of a phase I/II clinical study. Int J Radiat Oncol Biol Phys; 2007 Jul 1;68(3):786-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypofractionated high-dose proton beam therapy for stage I non-small-cell lung cancer: preliminary results of a phase I/II clinical study.
  • PURPOSE: To present treatment outcomes of hypofractionated high-dose proton beam therapy for Stage I non-small-cell lung cancer (NSCLC).
  • Histology was squamous cell carcinoma in 6 patients, adenocarcinoma in 14, and large cell carcinoma in 1.
  • Five patients showed recurrences 6-29 months after treatment, including local progression and new lung lesions outside of the irradiated volume in 1 and 4 patients, respectively.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / radiotherapy. Dose Fractionation. Lung Neoplasms / radiotherapy. Neoplasm Recurrence, Local / prevention & control. Protons / therapeutic use

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17379439.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protons
  •  go-up   go-down


39. Okamoto T, Ichinose Y: [Adjuvant chemotherapy for non-small cell lung cancer]. Gan To Kagaku Ryoho; 2006 Dec;33(13):1985-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adjuvant chemotherapy for non-small cell lung cancer].
  • Recently, several randomized trials with a large number of enrolled patients have shown that postoperative adjuvant treatment improves survival among patients with completely resected non-small cell lung cancer (NSCLC).
  • On the other hand, uracil-tegafur was also shown to improve survival among patients with stage I adenocarcinoma in Japan.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / surgery. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Combined Modality Therapy. Drug Combinations. Humans. Meta-Analysis as Topic. Pneumonectomy. Randomized Controlled Trials as Topic. Survival Rate. Tegafur / administration & dosage. Uracil / administration & dosage. Vinblastine / administration & dosage. Vinblastine / analogs & derivatives

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. VINORELBINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17197740.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / UFT(R) drug; 1548R74NSZ / Tegafur; 56HH86ZVCT / Uracil; 5V9KLZ54CY / Vinblastine; Q20Q21Q62J / Cisplatin; Q6C979R91Y / vinorelbine
  • [Number-of-references] 12
  •  go-up   go-down


40. Miyamoto H, Wang Z, Fukai R, Futagawa T, Anami Y, Yamazaki A, Morio A, Hata E: Complete resection via medial sternotomy for non-small cell lung cancer in the right upper lobe. ANZ J Surg; 2005 Dec;75(12):1049-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete resection via medial sternotomy for non-small cell lung cancer in the right upper lobe.
  • BACKGROUND: Right upper lobectomy with right cervical and bilateral mediastinal lymph node dissection via a median approach was performed for non-small cell lung cancer.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / surgery. Lung Neoplasms / surgery. Pneumonectomy / methods
  • [MeSH-minor] Adenocarcinoma / surgery. Aged. Female. Humans. Lymph Node Excision / methods. Male. Middle Aged. Neoplasm Staging. Sternum / surgery. Survival Analysis


41. Wang C, Zhang S, Ma Y, Ren B, Guo W, Hu C, Wang X, Feng S: [Bronchoplasty and pulmonary arterioplasty for central-type lung cancer]. Zhongguo Fei Ai Za Zhi; 2006 Feb 20;9(1):22-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Bronchoplasty and pulmonary arterioplasty for central-type lung cancer].
  • BACKGROUND: Bronchoplasty plus pulmonary arterioplasty has become one of the standard surgical operation for central-type lung cancer.
  • The aim of this study is to review the surgical experience of bronchoplasty and pulmonary arterioplasty in treatment of central-type lung cancer.
  • METHODS: From 1987 to 2005, 56 patients with central-type lung cancer underwent bronchoplasty and pulmonary arterioplasty.
  • Histologically, there were 35 cases of squamous cell carcinoma, 14 cases of adenocarcinoma, 4 cases of small cell lung cancer and 3 cases of carcinoid.
  • Bronchoplasty and pulmonary arterioplasty can be achieved with satisfactory outcome for central-type lung cancer, especially for those patients with advanced lesions or poor pulmonary function.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21144275.001).
  • [ISSN] 1009-3419
  • [Journal-full-title] Zhongguo fei ai za zhi = Chinese journal of lung cancer
  • [ISO-abbreviation] Zhongguo Fei Ai Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


42. Uchihara T, Okubo C, Tanaka R, Minami Y, Inadome Y, Iijima T, Morishita Y, Fujita J, Noguchi M: Neuronatin expression and its clinicopathological significance in pulmonary non-small cell carcinoma. J Thorac Oncol; 2007 Sep;2(9):796-801
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neuronatin expression and its clinicopathological significance in pulmonary non-small cell carcinoma.
  • The purpose of this study was to clarify the significance of neuronatin expression in pulmonary non-small cell carcinoma.
  • METHODS: We determined the frequency of neuronatin expression in surgically resected samples from non-small cell lung carcinoma (51 adenocarcinoma and 41 squamous cell carcinoma) by immunohistochemical staining, and investigated the correlations between expression level and various clinicopathological features.
  • RESULTS: Expression of neuronatin was observed more frequently in squamous cell carcinoma (63%) than in adenocarcinoma (25%).
  • In most cases, nontumorous lung tissue did not react with the antibody against neuronatin.
  • In both adenocarcinoma and squamous cell carcinoma, less differentiated tumors expressed neuronatin more frequently than did differentiated tumors.
  • In adenocarcinoma, but not squamous cell carcinoma, the prognosis of neuronatin-positive cases was significantly worse than that of neuronatin-negative cases.
  • CONCLUSION: Neuronatin expression is specific for tumor tissue and was detected in both pulmonary adenocarcinoma and squamous cell carcinoma at high frequency, particularly in less differentiated tumors.
  • Neuronatin expression is associated with poor prognosis in patients with adenocarcinoma, and may be useful as a prognostic marker for lung adenocarcinoma.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung. Gene Expression Regulation, Neoplastic. Lung Neoplasms. Membrane Proteins / genetics. Nerve Tissue Proteins / genetics. RNA, Neoplasm / genetics

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17805055.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Neoplasm; 0 / Biomarkers, Tumor; 0 / Membrane Proteins; 0 / NNAT protein, human; 0 / Nerve Tissue Proteins; 0 / RNA, Neoplasm
  •  go-up   go-down


43. Chen XL, Wang LC, Zhang WG, Chen XY, Sun ZM: [Correlations of S100A4 and MMP9 expressions to infiltration, metastasis and prognosis of non-small cell lung cancer]. Nan Fang Yi Ke Da Xue Xue Bao; 2008 Jul;28(7):1254-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Correlations of S100A4 and MMP9 expressions to infiltration, metastasis and prognosis of non-small cell lung cancer].
  • OBJECTIVE: To observe the expressions of metastasis-associated protein (S100A4) and matrix metalloproteinase 9 (MMP9) in human non-small cell lung cancer (NSCLC) and investigate their correlations to the infiltration, metastasis and prognosis of NSCLC.
  • METHODS: The expressions of S100A4 and MMP9 were detected in 41 NSCLC specimens and 6 normal lung tissue specimens using immunohistochemistry with SP method.
  • RESULTS: Compared with normal lung tissues, NSCLC showed significantly increased positivity for S100A4 and MMP9 expression (P<0.05); their expression were significantly higher in adenocarcinoma than in squamous cell carcinoma (P<0.01), and higher in metastatic NSCLC than in that without lymphatic metastasis (P<0.01).
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / metabolism. Lung Neoplasms / metabolism. Matrix Metalloproteinase 9 / biosynthesis. S100 Proteins / biosynthesis

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18676277.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / S100 Proteins; 142662-27-9 / S100A4 protein, human; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


44. Choi YD, Han CW, Kim JH, Oh IJ, Lee JS, Nam JH, Juhng SW, Park CS: Effectiveness of sputum cytology using ThinPrep method for evaluation of lung cancer. Diagn Cytopathol; 2008 Mar;36(3):167-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effectiveness of sputum cytology using ThinPrep method for evaluation of lung cancer.
  • Sputum cytology is a non-invasive test for evaluating lung cancer.
  • Sputum cytology using the TP method improves the diagnostic accuracy for evaluating lung cancer by reducing the unsatisfactory and false-negative rates.
  • [MeSH-major] Carcinoma / diagnosis. Histocytological Preparation Techniques. Lung Neoplasms / diagnosis. Sputum / cytology
  • [MeSH-minor] Adenocarcinoma / diagnosis. Carcinoma, Large Cell / diagnosis. Carcinoma, Small Cell / diagnosis. Carcinoma, Squamous Cell / diagnosis. Cytodiagnosis / methods. Humans. Predictive Value of Tests. Reproducibility of Results

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18232006.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


45. Lonardo F, Li X, Siddiq F, Singh R, Al-Abbadi M, Pass HI, Sheng S: Maspin nuclear localization is linked to favorable morphological features in pulmonary adenocarcinoma. Lung Cancer; 2006 Jan;51(1):31-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Maspin nuclear localization is linked to favorable morphological features in pulmonary adenocarcinoma.
  • Specifically, a nuclear, opposed to a combined nuclear and cytoplasmic localization has been associated with increased survival in human malignancies, including non-small cell lung cancer (NSCLC).
  • However, it is not known whether transformation affects maspin expression during lung carcinogenesis, and whether its subcellular localization correlates with the morphological features of NSCLC.
  • Immunohistochemistry revealed maspin expression to be virtually universal in NSCLC, occurring in 72/77 Adenocarcinoma (ACa), and 46/46 squamous cell carcinoma (SqCCa).
  • SqCCa showed almost exclusively a combined nuclear-cytosolic stain.
  • In contrast, nuclear maspin, but not combined nuclear-cytoplasmic maspin significantly correlated with low histological grade, lower proliferative rate, absence of invasion, and negative p53 stain in ACa.
  • [MeSH-major] Adenocarcinoma / metabolism. Cell Nucleus / metabolism. Lung Neoplasms / metabolism. Serine Proteinase Inhibitors / pharmacokinetics. Serpins / pharmacokinetics
  • [MeSH-minor] Blotting, Western. Bronchi / drug effects. Bronchi / metabolism. Bronchi / pathology. Cell Line, Tumor. Cytoplasm / metabolism. Genes, Tumor Suppressor. Humans. Immunohistochemistry. In Vitro Techniques

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16159682.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA84176
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / SERPIN-B5; 0 / Serine Proteinase Inhibitors; 0 / Serpins
  •  go-up   go-down


46. Gascon P, Pirker R, Del Mastro L, Durrwell L: Effects of CERA (continuous erythropoietin receptor activator) in patients with advanced non-small-cell lung cancer (NSCLC) receiving chemotherapy: results of a phase II study. Ann Oncol; 2010 Oct;21(10):2029-39
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of CERA (continuous erythropoietin receptor activator) in patients with advanced non-small-cell lung cancer (NSCLC) receiving chemotherapy: results of a phase II study.
  • The objective of this study was to select a starting dose of CERA for the treatment of anemia in non-small-cell lung cancer (NSCLC) patients.

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Anemia.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20335369.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Recombinant Proteins; 0 / continuous erythropoietin receptor activator; 11096-26-7 / Erythropoietin; 30IQX730WE / Polyethylene Glycols
  •  go-up   go-down


47. Izquierdo-Garcia FM, Moreno-Mata N, Herranz-Aladro ML, Cañizares MA, Alvarez-Fernandez E: Lung carcinoma with rhabdoid component. A series of seven cases associated with uncommon types of non-small cell lung carcinomas and alveolar entrapment. Histol Histopathol; 2010 10;25(10):1287-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lung carcinoma with rhabdoid component. A series of seven cases associated with uncommon types of non-small cell lung carcinomas and alveolar entrapment.
  • Rhabdoid tumor, included in the WHO classification among large cell carcinomas of the lung, is an uncommon type of lung carcinoma with poor prognosis.
  • We report a series of 7 cases of lung carcinomas with rhabdoid component in 10% and 80% of the tumor.
  • The associated tumor was adenocarcinoma in 3 cases--one of them with focal micropapillary pattern--large cell carcinoma in 2 cases, squamous cell carcinoma in 1 case and pleomorphic carcinoma in 1 case.
  • Two adenocarcinomas showed a focal spindle cell component.
  • Alveolar trapping inside the tumor was present in 3 cases--a phenomenon not well studied in lung carcinomas and also not reported in tumors with rhabdoid component.
  • In summary, we describe 7 new cases of this uncommon lung tumor with aggressive clinical course, associated with infrequent histological types in nonrhabdoid component and with alveolar trapping, a nondescribed finding.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Large Cell / pathology. Carcinoma, Non-Small-Cell Lung / pathology. Carcinoma, Squamous Cell / pathology. Lung Neoplasms / pathology. Pulmonary Alveoli / pathology. Rhabdoid Tumor / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20712013.001).
  • [ISSN] 1699-5848
  • [Journal-full-title] Histology and histopathology
  • [ISO-abbreviation] Histol. Histopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


48. Leinonen T, Pirinen R, Böhm J, Johansson R, Kosma VM: Increased expression of matrix metalloproteinase-2 (MMP-2) predicts tumour recurrence and unfavourable outcome in non-small cell lung cancer. Histol Histopathol; 2008 06;23(6):693-700
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased expression of matrix metalloproteinase-2 (MMP-2) predicts tumour recurrence and unfavourable outcome in non-small cell lung cancer.
  • The purpose of this study was to analyse the expression of matrix metalloproteinase-2 (MMP-2) and its extracellular matrix metalloproteinase inducer (EMMPRIN) in non-small cell lung cancer (NSCLC), and to evaluate their significance to predict tumour behaviour.
  • Adenocarcinomas showed more often high expression of MMP-2 as compared with squamous cell or large cell carcinomas (p=0.001).
  • High cancer cell associated MMP-2 expression was associated with increased tumour recurrence (p=0.001).
  • The high stromal MMP-2 expression was noticed more often among large cell carcinomas as compared with other histological types (p=0.007).
  • High cancer cell associated EMMPRIN expression was found in 115 (61%) cases and was associated only with high MMP-2 expression in tumour cells (p=0.006).
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / enzymology. Lung Neoplasms / enzymology. Matrix Metalloproteinase 2 / metabolism. Neoplasm Recurrence, Local
  • [MeSH-minor] Adenocarcinoma / enzymology. Adenocarcinoma / mortality. Adenocarcinoma / secondary. Adult. Aged. Antigens, CD147 / metabolism. Biomarkers, Tumor / metabolism. Carcinoma, Large Cell / enzymology. Carcinoma, Large Cell / mortality. Carcinoma, Large Cell / secondary. Carcinoma, Squamous Cell / enzymology. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / secondary. Disease-Free Survival. Finland / epidemiology. Humans. Immunoenzyme Techniques. Middle Aged. Neoplasm Staging. Predictive Value of Tests. Survival Rate

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18366007.001).
  • [ISSN] 1699-5848
  • [Journal-full-title] Histology and histopathology
  • [ISO-abbreviation] Histol. Histopathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / BSG protein, human; 0 / Biomarkers, Tumor; 136894-56-9 / Antigens, CD147; EC 3.4.24.24 / Matrix Metalloproteinase 2
  •  go-up   go-down


49. Sato K, Tomizawa Y, Iijima H, Saito R, Ishizuka T, Nakajima T, Mori M: Epigenetic inactivation of the RUNX3 gene in lung cancer. Oncol Rep; 2006 Jan;15(1):129-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epigenetic inactivation of the RUNX3 gene in lung cancer.
  • We examined RUNX3 expression by reverse transcription-PCR and the methylation status of this gene by methylation specific-PCR in 43 lung cancer cell lines and 120 primary non-small cell lung cancer (NSCLC) tumor samples.
  • RUNX3 expression was absent in 10 (50%) of 20 small cell lung cancer (SCLC) cell lines, 8 (50%) of 16 adenocarcinoma (AdC) cell lines, and 1 (33.3%) of 3 squamous cell carcinoma (SqC) cell lines.
  • The frequency of RUNX3 methylation was significantly higher in AdC (7/16, 43.8%) than SCLC cell lines (1/20, 5%; p=0.032).
  • RUNX3 expression was restored by treatment with 5-aza-2'-deoxycytidine and/or trichostatin-A in AdC cell lines.
  • These results indicated that RUNX3 expression was regulated by aberrant hypermethylation in AdC cell lines.
  • These results indicated that silencing of the RUNX3 gene plays an important role in the pathogenesis of lung cancer, and aberrant methylation is an important mechanism of inactivation of the RUNX3 gene in lung AdC.
  • [MeSH-major] Core Binding Factor Alpha 3 Subunit / genetics. DNA Methylation. Gene Silencing. Genes, Tumor Suppressor. Lung Neoplasms / genetics
  • [MeSH-minor] Cell Line, Tumor. DNA, Neoplasm / metabolism. Epigenesis, Genetic. Gene Expression. Humans

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16328045.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 3 Subunit; 0 / DNA, Neoplasm; 0 / Runx3 protein, human
  •  go-up   go-down


50. Feskanich D, Bain C, Chan AT, Pandeya N, Speizer FE, Colditz GA: Aspirin and lung cancer risk in a cohort study of women: dosage, duration and latency. Br J Cancer; 2007 Nov 5;97(9):1295-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aspirin and lung cancer risk in a cohort study of women: dosage, duration and latency.
  • Aspirin may reduce the risk of cancer at some sites but its effect at the lung is unclear.
  • We prospectively examined associations between aspirin use and risk of lung cancer in 109,348 women in the Nurses' Health study from 1980 to 2004.
  • During this time, 1,360 lung cancers were documented in participants 36-82 years of age.
  • Risk of lung cancer was a non-significant 16% lower for regular aspirin users of one or two tablets per week and a significant 55% higher for users of 15 or more tablets per week compared with women who never regularly used aspirin.
  • For both the low and high quantity aspirin users, risk of lung cancer did not decline or increase with longer durations of use, and associations attenuated as the latency period between aspirin assessment and lung cancer diagnosis was lengthened.
  • Our findings, together with those from previous clinical trials and prospective studies, do not provide consistent evidence that aspirin influences the development of lung cancer and further investigation is required with adjustment for smoking.


51. Zhang W, Chen Y, Wei H, Zheng C, Sun R, Zhang J, Tian Z: Antiapoptotic activity of autocrine interleukin-22 and therapeutic effects of interleukin-22-small interfering RNA on human lung cancer xenografts. Clin Cancer Res; 2008 Oct 15;14(20):6432-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antiapoptotic activity of autocrine interleukin-22 and therapeutic effects of interleukin-22-small interfering RNA on human lung cancer xenografts.
  • PURPOSE: Non-small cell lung carcinoma (NSCLC) is one of most common malignant diseases and usually is resistant against apoptosis-inducing chemotherapy.
  • This study is to explore the antiapoptotic mechanisms of interleukin (IL)-22 in human lung cancer.
  • Stable transfection of human IL-22 cDNA into A549 and PG cells and transfection of IL-22-RNA interference (RNAi) into these cancer cell lines were done to reveal the molecular mechanisms of IL-22.
  • IL-22R1 mRNA was also detected in lung cancer tissues as well as lung cancer cell lines.
  • Overexpression of IL-22 protected lung cancer cell lines from serum starvation-induced and chemotherapeutic drug-induced apoptosis via activation of STAT3 and its downstream antiapoptotic proteins such as Bcl-2 and Bcl-xL and inactivation of extracellular signal-regulated kinase 1/2.
  • Exposure to blocking antibodies against IL-22R1 or transfection with the IL-22-RNAi plasmid in vitro resulted in apoptosis of these lung cancer cells via STAT3 and extracellular signal-regulated kinase 1/2 pathways.
  • Furthermore, an in vivo xenograft study showed that administration of IL-22-RNAi plasmids significantly inhibited the human tumor cell growth in BALB/c nude mice.
  • CONCLUSIONS: Our study indicates that autocrine production of IL-22 contributes to human lung cancer cell survival and resistance to chemotherapy through the up-regulation of antiapoptotic proteins.
  • [MeSH-major] Apoptosis / drug effects. Interleukins / genetics. Lung Neoplasms / therapy. RNA, Small Interfering / therapeutic use
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Adenocarcinoma / therapy. Animals. Blotting, Western. Carcinoma, Non-Small-Cell Lung / genetics. Carcinoma, Non-Small-Cell Lung / pathology. Carcinoma, Non-Small-Cell Lung / therapy. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / therapy. Case-Control Studies. Caspases / metabolism. Cell Proliferation. Humans. Immunoenzyme Techniques. Lung / metabolism. Lung / pathology. Male. Mice. Mice, Inbred BALB C. Mice, Nude. Mitogen-Activated Protein Kinase 1 / metabolism. Mitogen-Activated Protein Kinase 3 / metabolism. Pleural Effusion, Malignant / genetics. Pleural Effusion, Malignant / pathology. Pleural Effusion, Malignant / therapy. RNA, Messenger / genetics. RNA, Messenger / metabolism. Receptors, Interleukin / genetics. Receptors, Interleukin / metabolism. Reverse Transcriptase Polymerase Chain Reaction. STAT3 Transcription Factor / metabolism. Transplantation, Heterologous. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18927282.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interleukins; 0 / RNA, Messenger; 0 / RNA, Small Interfering; 0 / Receptors, Interleukin; 0 / STAT3 Transcription Factor; 0 / interleukin-22; 0 / interleukin-22 receptor; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 1; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 3; EC 3.4.22.- / Caspases
  •  go-up   go-down


52. Chuang TY, Yu CJ, Shih JY, Yang PC, Kuo SH: Cytologically proven meningeal carcinomatosis in patients with lung cancer: clinical observation of 34 cases. J Formos Med Assoc; 2008 Nov;107(11):851-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytologically proven meningeal carcinomatosis in patients with lung cancer: clinical observation of 34 cases.
  • BACKGROUND/PURPOSE: Meningeal carcinomatosis (MC) is a rare neurologic complication of lung cancer.
  • Occasionally, it is the initial presentation of lung cancer.
  • The clinical features of MC exclusively in lung cancer patients have not been well identified and characterized.
  • The purpose of this report is to disclose the clinical features, laboratory findings, treatment and survival of patients with MC from lung cancer.
  • METHODS: We reviewed the medical records of 34 lung cancer patients with cytologically diagnosed MC at National Taiwan University Hospital from 1992 to 2002.
  • Clinical symptoms and signs, cerebrospinal fluid parameters and lung cancer staging at the time of presentation were summarized.
  • Previous treatment modalities for lung cancer, various treatments and response of MC, complications and survival times were also analyzed.
  • RESULTS: Cerebrospinal fluid cytology revealed adenocarcinoma in 32 patients, and small cell carcinoma and squamous cell carcinoma in one each.
  • MC occurred in approximately 0.7% of lung cancer patients.
  • Nine patients had MC as the initial presentation of lung cancer.
  • CONCLUSION: The prognosis of MC from lung cancer is poor.
  • A prospective study is needed to establish the effectiveness of combined modality therapy for patients with MC from lung cancer.

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18971154.001).
  • [ISSN] 0929-6646
  • [Journal-full-title] Journal of the Formosan Medical Association = Taiwan yi zhi
  • [ISO-abbreviation] J. Formos. Med. Assoc.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Singapore
  •  go-up   go-down


53. Kris MG: How today's developments in the treatment of non-small cell lung cancer will change tomorrow's standards of care. Oncologist; 2005 Oct;10 Suppl 2:23-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] How today's developments in the treatment of non-small cell lung cancer will change tomorrow's standards of care.
  • Cisplatin (Platinol; Bristol-Myers Squibb, Princeton, NJ, http://www.bms.com) and carboplatin (Paraplatin; Bristol-Myers Squibb), together with newer chemotherapies, such as docetaxel (Taxotere; Aventis Pharmaceuticals Inc., Bridgewater, NJ, http://www.aventispharma-us.com), paclitaxel (Taxol; Bristol-Myers Squibb), vinorelbine (Navelbine; GlaxoSmith-Kline, Philadelphia, http://www.gsk.com), pemetrexed (Alimta; Eli Lilly and Company, Indianapolis, http://www.lilly.com), and gemcitabine (Gemzar; Eli Lilly and Company), have improved treatment outcomes in both advanced non-small cell lung cancer (NSCLC) and in the adjuvant/neoadjuvant setting.
  • Clinical characteristics, such as never smoking status and adenocarcinoma, and especially bronchioloalveolar carcinoma histological features, can also identify individuals likely to respond to EGFR tyrosine kinase inhibitors.
  • Effective development of active agents and disease management based on molecular profiling of lung tumors will change tomorrow's standard of care.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / therapy. Chemotherapy, Adjuvant. Lung Neoplasms / therapy


54. Zhou CC, Zhou SW, Pan H, Su B, Gao ZQ: [Detection of epidermal growth factor receptor mutations in non-small cell lung cancer by real-time PCR using TaqMan-MGB probes]. Zhonghua Zhong Liu Za Zhi; 2007 Feb;29(2):119-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Detection of epidermal growth factor receptor mutations in non-small cell lung cancer by real-time PCR using TaqMan-MGB probes].
  • OBJECTIVE: To investigate mutations of EGFR TK gene in non-small cell lung cancer (NSCLC) and the diagnostic value of the mutations assayed by real-time PCR using TaqMan-MGB probes.
  • Real-time PCR with TagMan MGB probes could detect EGFR mutation in as rare as 50 EGFR mutant cells and in a proportion of 10% of mutant cells in a cell population.
  • The mutations were significantly higher in the adenocarcinoma than in non-adenocarcinoma (16/38 vs. 5/42, chi2 = 9.702, P <0.01), in the female patients than in the male patients (14/29 vs. 7/51, chi2 = 11.4, P <0.01) and in non-smokers than in smokers (16/40 vs. 5/40, chi2 = 7.812, P < 0.01).
  • CONCLUSION: Somatic mutations of EGFR gene develop in NSCLC and are more common in female, non-smoker and adenocarcinoma patients.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / genetics. Lung Neoplasms / genetics. Mutation. Polymerase Chain Reaction / methods. Receptor, Epidermal Growth Factor / genetics
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Adult. Aged. Aged, 80 and over. Base Sequence. Cell Line, Tumor. Chi-Square Distribution. Codon. DNA Mutational Analysis. DNA Probes / genetics. Exons. Female. Gene Deletion. Humans. Male. Middle Aged. Neoplasm Staging. Sex Factors. Smoking


55. Ciriaco P, Casiraghi M, Melloni G, Carretta A, Libretti L, Augello G, Zannini P: Pulmonary resection for non-small-cell lung cancer in patients on hemodialysis: clinical outcome and long-term results. World J Surg; 2005 Nov;29(11):1516-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary resection for non-small-cell lung cancer in patients on hemodialysis: clinical outcome and long-term results.
  • The aim of the study was to analyze the postoperative outcome in terms of complications and survival of a group of patients on HD who had undergone pulmonary resection for non-small cell lung cancer (NSCLC).
  • The histologic diagnosis was squamous cell carcinoma in four cases and adenocarcinoma in three.
  • One patient underwent two lung resections in 4 years for two primary lung cancers.
  • Patients on HD who undergo lung resection have a high rate of postoperative complications.
  • Although the underlying disease influences long-term survival, radical lung resection in NSCLC patients is recommended in selected cases.
  • [MeSH-major] Adenocarcinoma / surgery. Carcinoma, Squamous Cell / surgery. Kidney Failure, Chronic / epidemiology. Lung Neoplasms / surgery. Pneumonectomy. Renal Dialysis


56. Ganti AK: Epidermal growth factor receptor signaling in nonsmall cell lung cancer. Cancer Invest; 2010 Jun;28(5):515-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidermal growth factor receptor signaling in nonsmall cell lung cancer.
  • Epidermal growth factor is a 170-kd protein that binds to a specific tyrosine kinase receptor, epidermal growth factor receptor (EGFR), on the cell surface.
  • EGFR function is dysregulated in various malignancies including nonsmall cell lung cancer (NSCLC) leading to activation of several signal transduction pathways including K-RAS, PIK3, and STAT3 and STAT5, that promote cell cycle progression, proliferation, invasion, angiogenesis, and inhibit apoptosis.
  • EGFR inhibitors currently undergoing clinical trials in NSCLC include monoclonal antibodies or small molecule tyrosine kinase inhibitors.
  • The only EGFR inhibitor currently approved for the treatment of NSCLC is erlotinib, a small molecule tyrosine kinase inhibitor.
  • Although women, nonsmokers, patients with adenocarcinoma and patients with Asian ethnicity seem to have better outcomes with erlotinib, the factors predictive for response to these agents are currently the focus of investigation.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / metabolism. Lung Neoplasms / metabolism. Protein Kinase Inhibitors / therapeutic use. Receptor, Epidermal Growth Factor / metabolism
  • [MeSH-minor] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Cell Line, Tumor. Clinical Trials as Topic. Drug Resistance, Neoplasm. Drug Screening Assays, Antitumor. Erlotinib Hydrochloride. Humans. Prognosis. Quinazolines / therapeutic use. Signal Transduction

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20073576.001).
  • [ISSN] 1532-4192
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antineoplastic Agents; 0 / Protein Kinase Inhibitors; 0 / Quinazolines; DA87705X9K / Erlotinib Hydrochloride; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


57. Chiaviello A, Paciello I, Postiglione I, Crescenzi E, Palumbo G: Combination of photodynamic therapy with aspirin in human-derived lung adenocarcinoma cells affects proteasome activity and induces apoptosis. Cell Prolif; 2010 Oct;43(5):480-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination of photodynamic therapy with aspirin in human-derived lung adenocarcinoma cells affects proteasome activity and induces apoptosis.
  • OBJECTIVES: Photodynamic treatment (PDT) of human lung carcinoma cells A549 (p53(+/+)) and H1299 (p53(-/-)) induces fast but transient stalling of proteasome activity.
  • Under these conditions, we analysed cell viability, colony-forming efficiency, cycle profile, expression patterns of specific proteins and ubiquitination state, after individual or combined administration.
  • [MeSH-major] Apoptosis / drug effects. Aspirin / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Photochemotherapy / methods. Proteasome Endopeptidase Complex / metabolism
  • [MeSH-minor] Cell Cycle / drug effects. Cell Line, Tumor. Humans

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. ACETYLSALICYLIC ACID .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20887554.001).
  • [ISSN] 1365-2184
  • [Journal-full-title] Cell proliferation
  • [ISO-abbreviation] Cell Prolif.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 3.4.25.1 / Proteasome Endopeptidase Complex; R16CO5Y76E / Aspirin
  •  go-up   go-down


58. Nakata M, Sawada S, Yamashita M, Saeki H, Kurita A, Takashima S, Tanemoto K: Objective radiologic analysis of ground-glass opacity aimed at curative limited resection for small peripheral non-small cell lung cancer. J Thorac Cardiovasc Surg; 2005 Jun;129(6):1226-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Objective radiologic analysis of ground-glass opacity aimed at curative limited resection for small peripheral non-small cell lung cancer.
  • OBJECTIVE: The aim of this study was to evaluate the efficacy of the objective radiologic analysis of high-resolution computed tomographic images of small peripheral non-small cell lung cancer and to select the candidates for curative limited resection.
  • METHODS: High-resolution computed tomographic images of 146 surgically resected T1 N0 M0 peripheral non-small cell lung cancers were analyzed by using National Institutes of Health image software and classified on the basis of the percentage of ground-glass opacity within the tumor.
  • RESULTS: Eighty-seven percent of tumors with ground-glass opacity ratios of 90% to 100% (type I) were diagnosed as noninvasive bronchioloalveolar carcinoma, whereas 55.6% of tumors with ground-glass opacity ratios of 50% to 89% (type II) consisted of adenocarcinoma.
  • CONCLUSIONS: The objective quantitative radiologic analysis with National Institutes of Health image software exhibited a good correlation with the histologic classification, pathologic invasiveness, and postoperative outcome of small peripheral lung cancer.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / radiography. Carcinoma, Non-Small-Cell Lung / surgery. Lung Neoplasms / radiography. Lung Neoplasms / surgery. Software. Tomography, X-Ray Computed / methods


59. Boonananwong S, Kongkathip B, Kongkathip N: First synthesis of 3,16,20-polyoxygenated cholestanes, new cytotoxic steroids from the gorgonian Leptogorgia sarmentosa. Steroids; 2008 Oct;73(11):1123-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Antitumor activity against three tumor cell lines (breast cancer, MCF7, lung cancer NCI and oral cancer KB) was evaluated.
  • [MeSH-minor] Adenocarcinoma / drug therapy. Animals. Antineoplastic Agents / therapeutic use. Breast Neoplasms / drug therapy. Carcinoma, Small Cell / drug therapy. Carcinoma, Squamous Cell / drug therapy. Cell Line, Tumor. Drug Evaluation, Preclinical. Humans. Inhibitory Concentration 50. Lung Neoplasms / drug therapy. Molecular Structure. Mouth Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18550136.001).
  • [ISSN] 0039-128X
  • [Journal-full-title] Steroids
  • [ISO-abbreviation] Steroids
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Cholestanes; 0 / Cytotoxins; 0 / Steroids
  •  go-up   go-down


60. Ji H, Sharpless NE, Wong KK: EGFR targeted therapy: view from biological standpoint. Cell Cycle; 2006 Sep;5(18):2072-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Activating mutations in the kinase domain of the epidermal growth factor receptor (EGFR) in nonsmall cell lung cancers (NSCLCs) correlate with responsiveness to EGFR kinase inhibitors.
  • In vitro cell culture studies have demonstrated that EGFR kinase domain mutants but not wild type (wt) EGFR are transforming and essential for cancer cell survival.
  • We and others have recently demonstrated that the induction of EGFR kinase domain mutants specifically in murine lung epithelium in vivo led to development of adenocarcinoma with bronchioloalveolar carcinoma (BAC) features.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / therapy. Carcinoma, Non-Small-Cell Lung / metabolism. Carcinoma, Non-Small-Cell Lung / therapy. Drug Resistance, Neoplasm / physiology. Receptor, Epidermal Growth Factor / antagonists & inhibitors. Receptor, Epidermal Growth Factor / metabolism

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16969107.001).
  • [ISSN] 1551-4005
  • [Journal-full-title] Cell cycle (Georgetown, Tex.)
  • [ISO-abbreviation] Cell Cycle
  • [Language] eng
  • [Grant] United States / NIA NIH HHS / AG / AG24004; United States / NCI NIH HHS / CA / CA90679
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Enzyme Inhibitors; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  • [Number-of-references] 44
  •  go-up   go-down


61. Li XD, Geng YT, Wu CP, Shen H, Sun J, Shu YQ, Yin YM: Restoration of gefitinib efficacy following chemotherapy in a patient with metastatic non-small cell lung cancer. Onkologie; 2010;33(8-9):466-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Restoration of gefitinib efficacy following chemotherapy in a patient with metastatic non-small cell lung cancer.
  • BACKGROUND: Gefitinib has shown evidence of antitumor activity in advanced non-small cell lung cancer (NSCLC).
  • CASE REPORT: A female Asian nonsmoker with adenocarcinoma was given gefitinib as first-line treatment with significant efficacy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / secondary. Drug Resistance, Neoplasm / drug effects. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Quinazolines / administration & dosage

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 S. Karger AG, Basel.
  • (PMID = 20838064.001).
  • [ISSN] 1423-0240
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Quinazolines; S65743JHBS / gefitinib
  •  go-up   go-down


62. Lyons G, Quadrelli S, Silva C, Vera K, Iotti A, Venditti J, Chertcoff J, Chimondeguy D: Analysis of survival in 400 surgically resected non-small cell lung carcinomas: towards a redefinition of the T factor. J Thorac Oncol; 2008 Sep;3(9):989-93
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of survival in 400 surgically resected non-small cell lung carcinomas: towards a redefinition of the T factor.
  • There is controversy about the impact of tumor size itself as a variable unrelated to stage.The objective of this study was to analyze the influence of tumor size on the survival in patients with surgically resected non-small cell lung carcinoma (NSCLC).
  • METHODS: Between August 1985 and January 2006, 400 patients underwent pulmonary resection with a curative intention for non-small cell lung carcinoma.
  • Adenocarcinoma was the most common type (n = 245, 61.2%).
  • Univariate analysis for the group of pN0 patients showed survival was not significantly affected by age, sex, side, or adenocarcinoma histology.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / mortality. Carcinoma, Non-Small-Cell Lung / secondary. Lung Neoplasms / mortality. Lung Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18758301.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


63. van Puijenbroek R, Bosquée L, Meert AP, Schallier D, Goeminne JC, Tits G, Collard P, Nackaerts K, Canon JL, Duplaquet F, Galdermans D, Germonpré P, Azerad MA, Vandenhoven G, De Greve J, Vansteenkiste J: Gefitinib monotherapy in advanced nonsmall cell lung cancer: a large Western community implementation study. Eur Respir J; 2007 Jan;29(1):128-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gefitinib monotherapy in advanced nonsmall cell lung cancer: a large Western community implementation study.
  • Epidermal growth factor receptor tyrosine kinase inhibitors represent a new treatment option for patients with advanced nonsmall cell lung cancer (NSCLC).
  • Survival was strongly influenced by a better performance status (PS) (good PS: hazard ratio (HR) (95%CI) 0.110 (0.077-0.157)) and adenocarcinoma with bronchioloalveolar carcinoma features histology (HR (95%CI) 0.483 (0.279-0.834)).
  • Response, present in a small subgroup, led to a rewarding survival and could be predicted by sex only.
  • Baseline performance status and adenocarcinoma with bronchioloalveolar carcinoma features histology were significant factors for survival.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Quinazolines / therapeutic use


64. Martoni A, Marino A, Sperandi F, Giaquinta S, Di Fabio F, Melotti B, Guaraldi M, Palomba G, Preti P, Petralia A, Artioli F, Picece V, Farris A, Mantovani L: Multicentre randomised phase III study comparing the same dose and schedule of cisplatin plus the same schedule of vinorelbine or gemcitabine in advanced non-small cell lung cancer. Eur J Cancer; 2005 Jan;41(1):81-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multicentre randomised phase III study comparing the same dose and schedule of cisplatin plus the same schedule of vinorelbine or gemcitabine in advanced non-small cell lung cancer.
  • This study compares two cytotoxic regimens comprising the same dose and schedule of cisplatin (CP) plus vinorelbine (VNR) or gemcitabine (GEM) administered under the same schedule to patients with advanced non-small cell lung cancers (NSCLC).
  • Their main characteristics were: male/female ratio 214/58; median age 63 (range 32-77) years; median Karnofsky Performance Status (PS) 80 (range 70-100); stage IIIB 34%, stage IV 61%, recurrent disease 5%; histology - epidermoid 29%, adenocarcinoma 53%, other NSCLC 18%.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carcinoma, Non-Small-Cell Lung / drug therapy. Deoxycytidine / analogs & derivatives. Lung Neoplasms / drug therapy. Vinblastine / analogs & derivatives


65. Ramanakumar AV, Parent ME, Siemiatycki J: Risk of lung cancer from residential heating and cooking fuels in Montreal, Canada. Am J Epidemiol; 2007 Mar 15;165(6):634-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk of lung cancer from residential heating and cooking fuels in Montreal, Canada.
  • In the course of a case-control study of lung cancer carried out in Montreal in 1996-2001, the authors collected information on subjects' lifetime exposure to such sources of domestic pollution by means of a personal interview with the subject or a next-of-kin proxy.
  • [MeSH-major] Air Pollution, Indoor / adverse effects. Cooking. Heating / adverse effects. Lung Neoplasms / epidemiology
  • [MeSH-minor] Adenocarcinoma / epidemiology. Adult. Aged. Carcinoma, Small Cell / epidemiology. Case-Control Studies. Environmental Exposure / adverse effects. Environmental Exposure / analysis. Environmental Exposure / statistics & numerical data. Environmental Monitoring. Epidemiological Monitoring. Female. Humans. Logistic Models. Male. Middle Aged. Multivariate Analysis. Neoplasms, Squamous Cell / epidemiology. Quebec / epidemiology. Risk Factors. Sex Distribution. Smoking / adverse effects. Smoking / epidemiology. Socioeconomic Factors. Surveys and Questionnaires. Urban Health / statistics & numerical data


66. Yamashita K, Kawakami F, Nakashima Y, Murakami K: Clear cell carcinoma of the minor salivary gland: an autopsy case with multiple metastases 29 years after the initial surgery and a review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2009 Jun;107(6):819-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear cell carcinoma of the minor salivary gland: an autopsy case with multiple metastases 29 years after the initial surgery and a review of the literature.
  • Clear cell carcinoma of the salivary gland is an uncommon tumor comprising about 1% of neoplasms of minor salivary glands.
  • At the initial presentation, the patient was a 48-year-old man with a small ulcerative tumor in the right hard palate, and the tumor was excised.
  • Twenty-four years after the initial excision, the first recurrence was detected in the lung.
  • Specimens obtained at the initial excision and at autopsy were very similar histologically and immunohistochemically, and both were clear cell carcinoma of the salivary gland.
  • [MeSH-major] Adenocarcinoma, Clear Cell / secondary. Lung Neoplasms / secondary. Lymphatic Metastasis / pathology. Neoplasms, Second Primary / secondary. Salivary Gland Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19464657.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


67. Langer W, Sohler F, Leder G, Beckmann G, Seidel H, Gröne J, Hummel M, Sommer A: Exon array analysis using re-defined probe sets results in reliable identification of alternatively spliced genes in non-small cell lung cancer. BMC Genomics; 2010;11:676
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Exon array analysis using re-defined probe sets results in reliable identification of alternatively spliced genes in non-small cell lung cancer.
  • BACKGROUND: Treatment of non-small cell lung cancer with novel targeted therapies is a major unmet clinical need.
  • RESULTS: In this study, a genome-wide analysis of the alteration of splicing patterns between lung cancer and normal lung tissue was performed.
  • We generated an exon array data set derived from matched pairs of lung cancer and normal lung tissue including both the adenocarcinoma and the squamous cell carcinoma subtypes.
  • In total, 330 genes were found to be differentially spliced in non-small cell lung cancer compared to normal lung tissue.
  • Evidence was found that the activity of FOX2, the splicing factor shown to cause cancer-specific splicing patterns in breast and ovarian cancer, is not altered at the transcript level in several cancer types including lung cancer.
  • [MeSH-major] Alternative Splicing / genetics. Carcinoma, Non-Small-Cell Lung / genetics. DNA Probes / metabolism. Exons / genetics. Genes, Neoplasm / genetics. Lung Neoplasms / genetics. Oligonucleotide Array Sequence Analysis / methods


68. Doi M, Sugiyama T, Izumiyama H, Yoshimoto T, Hirata Y: Clinical features and management of ectopic ACTH syndrome at a single institute in Japan. Endocr J; 2010;57(12):1061-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Six cases deceased, including small cell carcinoma (2) and adenocarcinoma (1) of lung, neuroendocrine carcinoma of pancreas (1) and stomach (1), and olfactory neuroblastoma (1), whereas 4 cases survived after removal of the tumors, including bronchial carcinoid tumor (3) and thymic hyperplasia (1).
  • Thus, various endocrine tests combined with imaging studies are required to correctly localize the tumors.

  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • Hazardous Substances Data Bank. METYRAPONE .
  • Hazardous Substances Data Bank. Corticotropin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21076235.001).
  • [ISSN] 1348-4540
  • [Journal-full-title] Endocrine journal
  • [ISO-abbreviation] Endocr. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 7S5I7G3JQL / Dexamethasone; 9002-60-2 / Adrenocorticotropic Hormone; 9015-71-8 / Corticotropin-Releasing Hormone; WI4X0X7BPJ / Hydrocortisone; ZS9KD92H6V / Metyrapone
  •  go-up   go-down


69. Kato Y, Peled N, Wynes MW, Yoshida K, Pardo M, Mascaux C, Ohira T, Tsuboi M, Matsubayashi J, Nagao T, Ikeda N, Hirsch FR: Novel epidermal growth factor receptor mutation-specific antibodies for non-small cell lung cancer: immunohistochemistry as a possible screening method for epidermal growth factor receptor mutations. J Thorac Oncol; 2010 Oct;5(10):1551-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel epidermal growth factor receptor mutation-specific antibodies for non-small cell lung cancer: immunohistochemistry as a possible screening method for epidermal growth factor receptor mutations.
  • BACKGROUND: Epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC) predict better outcome to EGFR tyrosine kinase inhibitors.
  • Analysis for objective response rates and survival were not correlated to IHC staining, although the combined staining showed nonsignificant trends toward better overall survival for patients with EGFR mutations.

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2006 Jul 1;12(13):3908-14 [16818686.001]
  • [Cites] J Mol Diagn. 2006 Jul;8(3):335-41 [16825506.001]
  • [Cites] Cancer Sci. 2006 Jul;97(7):642-8 [16827805.001]
  • [Cites] Br J Cancer. 2006 Oct 23;95(8):1070-5 [17047654.001]
  • [Cites] Cancer. 2006 Dec 15;107(12):2858-65 [17096434.001]
  • [Cites] J Clin Oncol. 2007 Feb 10;25(5):587-95 [17290067.001]
  • [Cites] Nat Rev Cancer. 2007 Mar;7(3):169-81 [17318210.001]
  • [Cites] Ann Oncol. 2007 Apr;18(4):752-60 [17317677.001]
  • [Cites] Chest. 2007 Aug;132(2):597-602 [17573511.001]
  • [Cites] Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5385-90 [17875767.001]
  • [Cites] Cancer Sci. 2007 Dec;98(12):1817-24 [17888036.001]
  • [Cites] Br J Cancer. 2008 Mar 11;98(5):907-14 [18283321.001]
  • [Cites] Clin Cancer Res. 2008 Aug 1;14(15):4751-7 [18676744.001]
  • [Cites] Eur J Cancer. 2009 Jan;45(2):228-47 [19097774.001]
  • [Cites] Lung Cancer. 2009 Mar;63(3):315-21 [18760859.001]
  • [Cites] Clin Cancer Res. 2009 May 1;15(9):3023-8 [19366827.001]
  • [Cites] N Engl J Med. 2009 Sep 3;361(10):947-57 [19692680.001]
  • [Cites] N Engl J Med. 2009 Sep 3;361(10):958-67 [19692684.001]
  • [Cites] Mod Pathol. 2009 Oct;22(10):1341-50 [19648882.001]
  • [Cites] Intern Med. 2009;48(21):1905-7 [19881244.001]
  • [Cites] Eur Respir J. 2010 Feb;35(2):391-5 [19643949.001]
  • [Cites] J Mol Diagn. 2010 Mar;12(2):169-76 [20093391.001]
  • [Cites] Clin Chem. 2003 Jun;49(6 Pt 1):853-60 [12765979.001]
  • [Cites] N Engl J Med. 2004 May 20;350(21):2129-39 [15118073.001]
  • [Cites] Science. 2004 Jun 4;304(5676):1497-500 [15118125.001]
  • [Cites] J Natl Cancer Inst. 2005 Mar 2;97(5):339-46 [15741570.001]
  • [Cites] J Clin Oncol. 2005 Apr 10;23(11):2513-20 [15738541.001]
  • [Cites] Clin Cancer Res. 2005 Apr 15;11(8):2924-9 [15837743.001]
  • [Cites] J Mol Diagn. 2005 Aug;7(3):396-403 [16049312.001]
  • [Cites] Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):839-44 [16467097.001]
  • [Cites] Am J Clin Pathol. 2006 May;125(5):682-92 [16707368.001]
  • (PMID = 20697298.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA058187; United States / NCI NIH HHS / CA / P50-CA058187
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / DNA, Neoplasm; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  • [Other-IDs] NLM/ NIHMS225083; NLM/ PMC2946481
  •  go-up   go-down


70. Byrne BJ, Garst J: Epidermal growth factor receptor inhibitors and their role in non-small-cell lung cancer. Curr Oncol Rep; 2005 Jul;7(4):241-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidermal growth factor receptor inhibitors and their role in non-small-cell lung cancer.
  • The epidermal growth factor receptor (EGFR) is a promising target in the treatment of advanced stage non-small-cell lung cancer (NSCLC).
  • Further studies have identified female sex, nonsmokers, Asian race, good performance status, and adenocarcinoma histology as predictors of patient response to these agents.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / physiopathology. Lung Neoplasms / drug therapy. Lung Neoplasms / physiopathology. Receptor, Epidermal Growth Factor / antagonists & inhibitors


71. Prokakis C, Koletsis E, Apostolakis E, Panagopoulos N, Charoulis N, Velissaris D, Filos K, Dougenis D: Combined heart surgery and lung tumor resection. Med Sci Monit; 2008 Mar;14(3):CS17-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined heart surgery and lung tumor resection.
  • BACKGROUND: Combined heart surgery and lung resection remains a controversial issue.
  • CASE REPORTS: A retrospective study is presented of five male patients who underwent combined surgical treatment for heart and lung disease in a one-step procedure between November 2004 and November 2006.
  • The other two patients underwent pulmonary wedge resection, one combined with coronary bypass and the other with ascending aorta replacement.
  • CONCLUSIONS: Combined heart surgery and lung resection can be performed without increased mortality and/or morbidity.
  • [MeSH-major] Adenocarcinoma / surgery. Aortic Valve Stenosis / surgery. Carcinoma, Non-Small-Cell Lung / surgery. Carcinoma, Squamous Cell / surgery. Lung Neoplasms / surgery

  • Genetic Alliance. consumer health - Heart tumor.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18301362.001).
  • [ISSN] 1234-1010
  • [Journal-full-title] Medical science monitor : international medical journal of experimental and clinical research
  • [ISO-abbreviation] Med. Sci. Monit.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Poland
  •  go-up   go-down


72. Achille M, Gallegos-Ruiz M, Giaccone G, Soria JC: Response to erlotinib in first-line treatment of non-small-cell lung cancer in a white male smoker with squamous-cell histology. Clin Lung Cancer; 2006 Nov;8(3):214-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Response to erlotinib in first-line treatment of non-small-cell lung cancer in a white male smoker with squamous-cell histology.
  • Erlotinib, a potent inhibitor of the tyrosine-kinase (TK) activity of human epidermal growth factor receptor (HER1/EGFR), produces significant survival and quality of life benefits in patients with previously treated advanced-stage non-small-cell lung cancer.
  • Although the survival benefit from erlotinib was observed in varied subgroups of patients, the radiographic responses were more common in certain patient subgroups, such as women, never-smokers, patients with adenocarcinoma histology, patients of Asian ethnicity, and patients with presence of HER1/EGFR TK domain mutations.
  • Herein, we describe a white male former smoker with advancedstage squamous cell non-small-cell lung cancer, who responded to first-line erlotinib.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Lung Neoplasms / drug therapy. Protein Kinase Inhibitors / therapeutic use. Quinazolines / therapeutic use


73. Meguid RA, Hooker CM, Harris J, Xu L, Westra WH, Sherwood JT, Sussman M, Cattaneo SM 2nd, Shin J, Cox S, Christensen J, Prints Y, Yuan N, Zhang J, Yang SC, Brock MV: Long-term survival outcomes by smoking status in surgical and nonsurgical patients with non-small cell lung cancer: comparing never smokers and current smokers. Chest; 2010 Sep;138(3):500-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term survival outcomes by smoking status in surgical and nonsurgical patients with non-small cell lung cancer: comparing never smokers and current smokers.
  • BACKGROUND: Survival outcomes of never smokers with non-small cell lung cancer (NSCLC) who undergo surgery are poorly characterized.
  • RESULTS: Never smokers were significantly more likely than current smokers to be women (P < .01), older (P < .01), and to have adenocarcinoma (P < .01) and bronchioloalveolar carcinoma (P < .01).
  • CONCLUSIONS: Our findings suggest that smoking status at time of lung cancer diagnosis has little impact on the long-term survival of patients with NSCLC, especially after curative surgery.
  • Despite different etiologies between lung cancer in never and current smokers the prognosis is equally dismal.


74. Ebi N, Semba H, Tokunaga SJ, Takayama K, Wataya H, Kuraki T, Yamamoto H, Akamine SJ, Okamoto I, Nakanishi Y, Lung Oncology Group in Kyushu, Japan: A phase II trial of gefitinib monotherapy in chemotherapy-naïve patients of 75 years or older with advanced non-small cell lung cancer. J Thorac Oncol; 2008 Oct;3(10):1166-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II trial of gefitinib monotherapy in chemotherapy-naïve patients of 75 years or older with advanced non-small cell lung cancer.
  • BACKGROUND: Gefitinib has shown modest activity in patients with recurrent non-small cell lung cancer (NSCLC) after platinum-based chemotherapy.
  • Secondary endpoints were tolerability, disease-related symptom using lung cancer subscale (LCS) in FACT-L, progression free survival (PFS) and overall survival (OS).
  • Thirty-two patients were female (65%) and 40 patients had adenocarcinoma (82%).
  • There were four patients with possible interstitial lung disease including two treatment-related deaths.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Quinazolines / therapeutic use
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Aged. Aged, 80 and over. Carcinoma, Large Cell / drug therapy. Carcinoma, Large Cell / secondary. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / secondary. Female. Health Surveys. Humans. Kaplan-Meier Estimate. Male. Maximum Tolerated Dose. Neoplasm Staging. Prognosis. Quality of Life. Receptor, Epidermal Growth Factor / antagonists & inhibitors. Receptor, Epidermal Growth Factor / genetics. Survival Rate. Treatment Outcome


75. Dwivedi RC, Kazi R, Agrawal N, Chisholm E, St Rose S, Elmiyeh B, Rennie C, Pepper C, Clarke PM, Kerawala CJ, Rhys-Evans PH, Harrington KJ, Nutting CM: Comprehensive review of small bowel metastasis from head and neck squamous cell carcinoma. Oral Oncol; 2010 May;46(5):330-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comprehensive review of small bowel metastasis from head and neck squamous cell carcinoma.
  • Secondary tumours of small intestine account for 10% of all small bowel cancers.
  • The most common sites of primary tumour metastasizing to small bowel are uterus, cervix, colon, lung, breast and melanoma.
  • The majority of these metastatic tumours come from adenocarcinoma primaries; squamous cell carcinoma constitutes a very small proportion of all metastatic small intestinal lesions.
  • Metastasis to small bowel by head and neck squamous cell carcinoma is extremely rare and carries an unfavourable prognosis.
  • This work aims at specifying these characteristics by reviewing, compiling, analysing and reporting all published cases in the published literature on small bowel metastasis secondary to head and neck squamous cell carcinoma.
  • To the best of our knowledge, this is the first comprehensive review article on the small intestinal metastasis from head and neck squamous cell carcinoma.
  • [MeSH-major] Carcinoma, Squamous Cell / secondary. Head and Neck Neoplasms / pathology. Intestinal Neoplasms / secondary. Intestine, Small / pathology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20189444.001).
  • [ISSN] 1879-0593
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  •  go-up   go-down


76. Tian M, Yu L, Duan Y, Wang X: [The Correlation between CT Characteristics of Non-small Lung Cancer and the Performance of (18)F-FDG PET and the Expression of Glut1 Protein.]. Zhongguo Fei Ai Za Zhi; 2009 Jul 20;12(7):770-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The Correlation between CT Characteristics of Non-small Lung Cancer and the Performance of (18)F-FDG PET and the Expression of Glut1 Protein.].
  • BACKGROUND: Glut1 is the main carrier which intervenes the glucose uptake of cell, and the expression of Glut1 was positively correlated to the uptake of FDG.
  • The aim of this study is to select the CT characteristics and clinicopathological parameters which can reflect the levels of glucose metabolism of human non-small lung cancer (NSLC).
  • METHODS: Thirty-three cases of the NSLC (squamous carcinoma 11 cases and adenocarcinoma 22 cases) have undergone the scanning of FDG PET/CT before operation.
  • RESULTS: The positive rate of Glut1 was 66.67% (squamous carcinoma was 90.91% and adenocarcinoma was 54.55%).
  • The positive rate of Glut1 and SUVmax of squamous carcinoma were significant higher than adenocarcinoma (Pbilateral=0.037, Punilateral=0.045).
  • CONCLUSIONS: The study suggested that the levels of glucose metabolism of squamous carcinoma higher than adenocarcinoma, the diameter upper than 2 cm and the thin and short speculation were higher.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20719153.001).
  • [ISSN] 1999-6187
  • [Journal-full-title] Zhongguo fei ai za zhi = Chinese journal of lung cancer
  • [ISO-abbreviation] Zhongguo Fei Ai Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


77. Verma SK, Srivastava R, Kant S, Prasad R, Garg R, Ahmad I, Husain N: A study to evaluate asbestos fiber burden in lung and pleural malignancies. Indian J Med Sci; 2010 Jul;64(7):315-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A study to evaluate asbestos fiber burden in lung and pleural malignancies.
  • BACKGROUND: There is scarcity of data on asbestos fiber burden in lung and pleural malignancies.
  • AIM: To evaluate asbestos fiber burden in biopsy samples of suspected lung and pleural malignancies.
  • STUDY POPULATION: Suspected cases of lung and pleural malignancy.
  • Average burden in lung malignancies (11 patients) was 9.178 × 10 4 fibers/g and in pleural tissue (9 patients) was 9.332 × 10 4fibers/g.
  • Among the different cell types, mean fiber burden in squamous cell carcinoma was 8.99 × 10 4 fibers/g, in adenocarcinoma was 9.71 × 10 4 fibers/g, and in small cell carcinoma was 7.54 × 10 4 fibers/g.
  • CONCLUSION: Maximum number of fibers was found in adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / chemistry. Asbestos / analysis. Carcinoma, Squamous Cell / chemistry. Lung Neoplasms / chemistry. Pleural Neoplasms / chemistry. Small Cell Lung Carcinoma / chemistry

  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. ASBESTOS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22918072.001).
  • [ISSN] 1998-3654
  • [Journal-full-title] Indian journal of medical sciences
  • [ISO-abbreviation] Indian J Med Sci
  • [Language] eng
  • [Publication-type] Journal Article; Observational Study
  • [Publication-country] India
  • [Chemical-registry-number] 1332-21-4 / Asbestos
  •  go-up   go-down


78. Michel RG, Kinasewitz GT, Fung KM, Keddissi JI: Optical coherence tomography as an adjunct to flexible bronchoscopy in the diagnosis of lung cancer: a pilot study. Chest; 2010 Oct;138(4):984-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Optical coherence tomography as an adjunct to flexible bronchoscopy in the diagnosis of lung cancer: a pilot study.
  • Lung cancer is the leading cause of cancer-related deaths in the United States and the second most common type of cancer in both men and women.
  • The histopathologic diagnoses of the endobronchial masses included two small cell carcinomas, one squamous cell carcinoma, one adenocarcinoma, and one endobronchial schwannoma.
  • Preliminary results suggest that OCT imaging is a technically feasible adjunct to flexible bronchoscopy in the diagnosis of lung cancer.
  • This technology may in the future provide a noninvasive "optical biopsy," which could potentially guide the bronchoscopist to areas for biopsy or even obviate the need for conventional lung biopsies.
  • [MeSH-major] Bronchoscopy. Lung Neoplasms / diagnosis. Tomography, Optical Coherence / methods


79. Ruibal A, Abdulkader I, Gude F, Pombo M, León L, Barandela J, Sánchez-Salmón A: [The immunohistochemical expression of cyclooxygenase 2 is inversely associated with (18)F-FDG-PET SUV values in non-small-cell lung cancers. Initial results]. Rev Esp Med Nucl; 2009 Jan-Feb;28(1):11-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The immunohistochemical expression of cyclooxygenase 2 is inversely associated with (18)F-FDG-PET SUV values in non-small-cell lung cancers. Initial results].
  • MATERIAL AND METHOD: 45 patients (12 adenocarcinomas and 33 squamous cell carcinomas) were included in this study; the immunohistochemical expression of COX-2, MIB-1, p16 and EGFR was determined using tissue-array.
  • CONCLUSIONS: Our results suggest that: a) the expression of COX-2 > ++ is often found in this kind of lung cancer and is not associated with the clinical stage;.
  • b) the maxSUVs were not related to the stage and were lower in COX-2 > ++ tumours than in the other cases; and c) the different behaviour of both parameters can be explained by their correlation with cell proliferation (MIB1), EGFR and p16 expression.
  • [MeSH-major] Adenocarcinoma / enzymology. Carcinoma, Non-Small-Cell Lung / enzymology. Carcinoma, Squamous Cell / enzymology. Cyclooxygenase 2 / analysis. Fluorine Radioisotopes / pharmacokinetics. Fluorodeoxyglucose F18 / pharmacokinetics. Lung Neoplasms / enzymology. Neoplasm Proteins / analysis. Radiopharmaceuticals / pharmacokinetics

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19232171.001).
  • [ISSN] 0212-6982
  • [Journal-full-title] Revista española de medicina nuclear
  • [ISO-abbreviation] Rev Esp Med Nucl
  • [Language] spa
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Fluorine Radioisotopes; 0 / Neoplasm Proteins; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


80. Hwang JH, Lee JK, Lee NW, Lee KW: Primary small cell carcinoma of the endometrium: report of a case with immunochemical studies. J Reprod Med; 2010 Jan-Feb;55(1-2):81-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary small cell carcinoma of the endometrium: report of a case with immunochemical studies.
  • BACKGROUND: Small cell carcinoma (SCC) is a well-known tumor that occurs predominantly in the lung.
  • We report a case of an endometrial tumor that was a combination of an SCC and endometrioid adenocarcinoma with squamous components and that penetrated half of the thickness of the uterine wall.
  • [MeSH-major] Carcinoma, Small Cell / pathology. Endometrial Neoplasms / pathology

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20337215.001).
  • [ISSN] 0024-7758
  • [Journal-full-title] The Journal of reproductive medicine
  • [ISO-abbreviation] J Reprod Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD56; 0 / Synaptophysin
  •  go-up   go-down


81. Terashima T, Matsuzaki T, Ogawa R, Naitou A, Morishita T, Ishizaka A: [Combination chemotherapy with carboplatin and docetaxel for elderly patients with non-small-cell lung cancer]. Nihon Kokyuki Gakkai Zasshi; 2008 Jul;46(7):516-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Combination chemotherapy with carboplatin and docetaxel for elderly patients with non-small-cell lung cancer].
  • The efficacy and toxicity of treatment with carboplatin (AUC= 5)+ docetaxel (70mg/m2) were analyzed retrospectively in 27 elderly patients with advanced non-small-cell lung cancer (NSCLC) aged 70 years or more.
  • The performance status (ECOG), clinical stage, and tumor histology in the patients were as follows: PS: PS 0, 12 patients; PS 1, 11 patients; PS 2, 4 patients; disease stage: stage IIIA, 5 patients; stage IIIB, 11 patients; stage IV, 11 patients; tumor histology: adenocarcinoma, 18 patients; squamous cell carcinoma, 9 patients.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carboplatin / administration & dosage. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Taxoids / administration & dosage
  • [MeSH-minor] Adenocarcinoma / drug therapy. Aged. Aged, 80 and over. Carcinoma, Squamous Cell / drug therapy. Female. Humans. Male. Retrospective Studies

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18700567.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Taxoids; 15H5577CQD / docetaxel; BG3F62OND5 / Carboplatin
  •  go-up   go-down


82. Leinonen T, Pirinen R, Böhm J, Johansson R, Rinne A, Weber E, Kosma VM: Biological and prognostic role of acid cysteine proteinase inhibitor (ACPI, cystatin A) in non-small-cell lung cancer. J Clin Pathol; 2007 May;60(5):515-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biological and prognostic role of acid cysteine proteinase inhibitor (ACPI, cystatin A) in non-small-cell lung cancer.
  • AIM: To analyse the expression and prognostic role of ACPI in non-small-cell lung cancer (NSCLC).
  • METHOD: Histological samples from 199 patients with resected NSCLC were stained immunohistochemically for the expression of ACPI in normal and preneoplastic bronchial epithelium, and in various types of lung carcinomas.
  • High staining for ACPI was found in 74% (91/123) of squamous-cell carcinomas, whereas 16% (8/49) of adenocarcinomas and 30% of (8/27) large-cell carcinomas showed the high expression of ACPI (p<0.001).
  • Among squamous-cell carcinomas, low expression of ACPI was correlated with poor tumour differentiation (p=0.032).
  • [MeSH-major] Biomarkers, Tumor / metabolism. Carcinoma, Non-Small-Cell Lung / metabolism. Cystatins / metabolism. Cysteine Proteinase Inhibitors / metabolism. Lung Neoplasms / metabolism
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adult. Aged. Carcinoma, Large Cell / metabolism. Carcinoma, Large Cell / pathology. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Follow-Up Studies. Humans. Immunoenzyme Techniques. Middle Aged. Neoplasm Staging. Precancerous Conditions / metabolism. Prognosis. Survival Analysis

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2000 Mar;6(3):1052-62 [10741734.001]
  • [Cites] Pathol Res Pract. 1980 Dec;170(1-3):172-9 [18788161.001]
  • [Cites] Prostate. 2001 Sep 15;48(4):274-84 [11536307.001]
  • [Cites] Cancer. 2002 Jun 15;94(12):3141-9 [12115346.001]
  • [Cites] Cancer Lett. 2002 Dec 10;187(1-2):185-90 [12359367.001]
  • [Cites] Cell Mol Life Sci. 2002 Sep;59(9):1503-12 [12440772.001]
  • [Cites] Prostate. 2003 Mar 1;54(4):290-8 [12539227.001]
  • [Cites] Biochem Soc Symp. 2003;(70):179-99 [14587292.001]
  • [Cites] Acta Chem Scand B. 1975;29(7):772-80 [242173.001]
  • [Cites] Acta Histochem. 1978;63(2):183-92 [107702.001]
  • [Cites] Acta Histochem Suppl. 1980;22:325-9 [6789389.001]
  • [Cites] Virchows Arch B Cell Pathol Incl Mol Pathol. 1983;43(2):121-6 [6137100.001]
  • [Cites] Exp Pathol. 1984;26(2):67-70 [6548973.001]
  • [Cites] J Biochem. 1984 Nov;96(5):1437-42 [6441803.001]
  • [Cites] Anat Anz. 1986;161(3):215-30 [2424340.001]
  • [Cites] Acta Histochem. 1987;82(1):5-18 [3122506.001]
  • [Cites] Biol Chem Hoppe Seyler. 1992 Jul;373(7):595-604 [1515089.001]
  • [Cites] Acta Histochem. 1992;93(1):241-8 [1326833.001]
  • [Cites] Biol Chem Hoppe Seyler. 1995 Feb;376(2):71-80 [7794528.001]
  • [Cites] Int J Cancer. 1995 Jul 4;62(1):1-4 [7541394.001]
  • [Cites] Int J Gynecol Pathol. 1995 Jul;14(3):217-22 [8600072.001]
  • [Cites] Eur Arch Otorhinolaryngol. 1997;254 Suppl 1:S150-3 [9065652.001]
  • [Cites] Clin Exp Metastasis. 1997 Jul;15(4):368-81 [9219725.001]
  • [Cites] Adv Exp Med Biol. 1997;421:259-65 [9330706.001]
  • [Cites] Cancer Res. 1998 Feb 1;58(3):432-6 [9458085.001]
  • [Cites] Oncol Rep. 1998 Nov-Dec;5(6):1349-61 [9769367.001]
  • [Cites] Neoplasma. 1998;45(5):318-31 [9921922.001]
  • [Cites] Eur J Hum Genet. 2005 Feb;13(2):208-15 [15483648.001]
  • [Cites] Hum Pathol. 2005 Jan;36(1):44-50 [15712181.001]
  • [Cites] J Clin Pathol. 2001 May;54(5):391-5 [11328840.001]
  • (PMID = 16790691.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cystatins; 0 / Cysteine Proteinase Inhibitors
  • [Other-IDs] NLM/ PMC1994551
  •  go-up   go-down


83. Monaco SE, Schuchert MJ, Khalbuss WE: Diagnostic difficulties and pitfalls in rapid on-site evaluation of endobronchial ultrasound guided fine needle aspiration. Cytojournal; 2010;7:9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: One of the novel techniques utilizing fine needle aspiration (FNA) in the diagnosis of mediastinal and lung lesions is the endobronchial ultrasound (EBUS)-guided FNA.
  • The cytomorphology in the direct smears, cell block, and immunohistochemical stains were reviewed, along with the clinical history and other available information.
  • RESULTS: Two cases were identified with a nondefinitive diagnosis at ROSE that were later diagnosed as malignant (metastatic signet-ring cell adenocarcinoma and metastatic renal cell carcinoma (RCC)) on the final cytological diagnosis.
  • Three additional cases were identified with a ROSE and final diagnosis of malignant (large cell neuroendocrine carcinoma (LCNEC) and two squamous cell carcinomas), but raised important diagnostic dilemmas.
  • Neuroendocrine tumors can also be difficult due to the wide range of entities in the differential diagnosis, including benign lymphocytes, lymphomas, small and nonsmall cell carcinomas, and the lack of immunohistochemical stains at the time of ROSE.
  • Many of the difficulties faced can be attributed to the baseline cellularity of the aspirates, the bronchial contamination, the difficulty identifying neoplasms with bland cytology, the wide spectrum of diseases that can occur in the mediastinum with overlapping cytomorphologic features, the mismatch between the background material and the cell populations present, and the overall unfamiliarity with these types of specimens.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Diagn Cytopathol. 1995 Jun;12(4):327-33 [7544720.001]
  • [Cites] Ann Thorac Surg. 1997 Jan;63(1):180-5 [8993262.001]
  • [Cites] Br J Cancer. 1991 Aug;64(2):333-8 [1654075.001]
  • [Cites] Cancer. 1985 Oct 1;56(7):1624-9 [2992742.001]
  • [Cites] Acta Cytol. 1986 Nov-Dec;30(6):671-8 [3466503.001]
  • [Cites] Chest. 2004 Jul;126(1):122-8 [15249452.001]
  • [Cites] J Thorac Cardiovasc Surg. 2003 Dec;126(6):1900-5 [14688703.001]
  • [Cites] Chest. 2004 Jan;125(1):322-5 [14718460.001]
  • [Cites] Ann Thorac Surg. 2003 Jan;75(1):231-5; discussion 235-6 [12537221.001]
  • [Cites] Cancer. 2001 Dec 25;93(6):364-75 [11748576.001]
  • [Cites] Hum Pathol. 2001 Sep;32(9):918-25 [11567220.001]
  • [Cites] Diagn Cytopathol. 2001 Jan;24(1):58-64 [11135471.001]
  • [Cites] Histopathology. 2000 Jul;37(1):33-6 [10931216.001]
  • [Cites] Cancer. 2000 Jun 25;90(3):148-61 [10896328.001]
  • [Cites] Acta Cytol. 2000 Mar-Apr;44(2):251-4 [10740616.001]
  • [Cites] Cytopathology. 2010 Feb;21(1):6-26 [20015257.001]
  • [Cites] Cancer. 2009 Dec 25;117(6):482-90 [19834962.001]
  • [Cites] Adv Anat Pathol. 2010 Jan;17(1):12-22 [20032634.001]
  • [Cites] Ann Thorac Surg. 2009 Sep;88(3):896-900; discussion 901-2 [19699917.001]
  • [Cites] Acta Cytol. 2009 May-Jun;53(3):349-52 [19534283.001]
  • [Cites] Eur Respir J. 2009 May;33(5):1156-64 [19407050.001]
  • [Cites] Diagn Cytopathol. 2009 Feb;37(2):146-9 [19072982.001]
  • [Cites] Cancer. 2008 Dec 25;114(6):504-11 [18980289.001]
  • [Cites] Acta Cytol. 2008 Nov-Dec;52(6):687-90 [19068672.001]
  • [Cites] Ann Thorac Surg. 2008 Nov;86(5):1405-8 [19049722.001]
  • [Cites] Am J Clin Pathol. 2008 Sep;130(3):434-43 [18701418.001]
  • [Cites] Am J Surg Pathol. 2008 Aug;32(8):1175-81 [18580681.001]
  • [Cites] Diagn Cytopathol. 2008 Aug;36(8):581-5 [18618726.001]
  • [Cites] Pathology. 2008 Aug;40(5):545-6 [18604751.001]
  • [Cites] Ann Thorac Surg. 2008 Apr;85(4):1166-9; discussion 1169-70 [18355490.001]
  • [Cites] Ann Diagn Pathol. 2008 Apr;12(2):146-52 [18325478.001]
  • [Cites] Ann Thorac Surg. 2008 Jan;85(1):224-30 [18154815.001]
  • [Cites] Oncology. 2007;72(1-2):64-8 [18004078.001]
  • [Cites] Arch Pathol Lab Med. 2007 Nov;131(11):1700-8 [17979490.001]
  • [Cites] Acta Cytol. 2007 Sep-Oct;51(5):834-6 [17910359.001]
  • [Cites] Cytojournal. 2006;3:25 [17087831.001]
  • [Cites] Chest. 2006 Sep;130(3):710-8 [16963667.001]
  • [Cites] Diagn Cytopathol. 2006 May;34(5):355-7 [16604557.001]
  • [Cites] Acta Cytol. 2005 Nov-Dec;49(6):669-72 [16450911.001]
  • [Cites] Mod Pathol. 2006 Feb;19 Suppl 2:S41-70 [16446716.001]
  • [Cites] J Clin Oncol. 2005 Dec 1;23(34):8774-85 [16314638.001]
  • [Cites] Hum Pathol. 2005 May;36(5):465-73 [15948112.001]
  • [Cites] Diagn Cytopathol. 2005 Jun;32(6):336-40 [15880717.001]
  • [Cites] Am J Surg Pathol. 2005 Feb;29(2):179-87 [15644774.001]
  • [Cites] Diagn Cytopathol. 1999 Jun;20(6):339-49 [10352906.001]
  • [Cites] Acta Cytol. 1999 Mar-Apr;43(2):184-90 [10097707.001]
  • [Cites] Diagn Cytopathol. 1998 Jan;18(1):62-6 [9451560.001]
  • [Cites] Diagn Cytopathol. 1997 Dec;17(6):412-6 [9407200.001]
  • [Cites] Monogr Pathol. 1997;(39):40-59 [9249819.001]
  • [Cites] Acta Cytol. 1997 May-Jun;41(3):941-2 [9167731.001]
  • [Cites] Acta Cytol. 1995 May-Jun;39(3):539-42 [7762348.001]
  • (PMID = 20607094.001).
  • [ISSN] 1742-6413
  • [Journal-full-title] CytoJournal
  • [ISO-abbreviation] Cytojournal
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2895875
  • [Keywords] NOTNLM ; Cytopathology / EBUS / endobronchial ultrasound / fine needle aspiration
  •  go-up   go-down


84. Morgan MT, Nakanishi Y, Kroll DJ, Griset AP, Carnahan MA, Wathier M, Oberlies NH, Manikumar G, Wani MC, Grinstaff MW: Dendrimer-encapsulated camptothecins: increased solubility, cellular uptake, and cellular retention affords enhanced anticancer activity in vitro. Cancer Res; 2006 Dec 15;66(24):11913-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The cytotoxicity of the dendrimer-drug complex toward four different human cancer cell lines [human breast adenocarcinoma (MCF-7), colorectal adenocarcinoma (HT-29), non-small cell lung carcinoma (NCI-H460), and glioblastoma (SF-268)] is also reported, and low nmol/L IC(50) values are measured.
  • Cellular uptake and efflux measurements in MCF-7 cells show an increase of 16-fold for cellular uptake and an increase in drug retention within the cell when using the dendrimer vehicle.
  • [MeSH-minor] Antineoplastic Agents, Phytogenic / pharmacokinetics. Antineoplastic Agents, Phytogenic / therapeutic use. Biocompatible Materials. Biological Transport. Brain Neoplasms. Breast Neoplasms. Capsules. Carcinoma, Non-Small-Cell Lung. Cell Line, Tumor. Colorectal Neoplasms. Female. Glioblastoma. Humans. Lung Neoplasms. Magnetic Resonance Spectroscopy. Solubility

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17178889.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA104286
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Biocompatible Materials; 0 / Capsules; 0 / Dendrimers; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


85. Cadranel J, Lavolé A, Gounant V, Wislez M: [Other thoracic cancers. Bronchioloalveolar carcinoma and adenocarcinoma with bronchioloalveolar carcinoma feature: a clinico-pathological spectrum]. Rev Mal Respir; 2008 Oct;25(8 Pt 2):3S196-202
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Other thoracic cancers. Bronchioloalveolar carcinoma and adenocarcinoma with bronchioloalveolar carcinoma feature: a clinico-pathological spectrum].
  • Bronchioloalveolar carcinoma (BAC) is a primary pulmonary adenocarcinoma (ADC) developed from the terminal respiratory unit.
  • BAC and ADC-WBF affect more frequently women, non-smokers and Asian people than other non small cell carcinoma.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / pathology. Lung Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18971846.001).
  • [ISSN] 0761-8425
  • [Journal-full-title] Revue des maladies respiratoires
  • [ISO-abbreviation] Rev Mal Respir
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


86. Devesa SS, Bray F, Vizcaino AP, Parkin DM: International lung cancer trends by histologic type: male:female differences diminishing and adenocarcinoma rates rising. Int J Cancer; 2005 Nov 1;117(2):294-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] International lung cancer trends by histologic type: male:female differences diminishing and adenocarcinoma rates rising.
  • Lung cancer rates have peaked among men in many areas of the world, but rates among women continue to rise.
  • Most lung cancers are squamous cell carcinoma, small cell carcinoma, or adenocarcinoma; trends vary according to type.
  • Squamous cell carcinoma rates among males declined 30% or more in North America and some European countries while changing less dramatically in other areas; small cell carcinoma rates decreased less rapidly.
  • Squamous and small cell carcinoma rates among females generally rose, with the increases especially pronounced in the Netherlands and Norway.
  • In contrast, adenocarcinoma rates rose among males and females in virtually all areas, with the increases among males exceeding 50% in many areas of Europe; among females, rates also rose rapidly and more than doubled in Norway, Italy and France.
  • Rates of all lung cancer types among women and adenocarcinoma among men continue to rise despite declining cigarette use in many Western countries and shifts to filtered/low-tar cigarettes.
  • Renewed efforts toward cessation and prevention are mandatory to curb the prevalence of cigarette smoking and to reduce lung cancer rates eventually.
  • [MeSH-major] Adenoma / epidemiology. Lung Neoplasms / classification. Lung Neoplasms / epidemiology
  • [MeSH-minor] Adenocarcinoma / epidemiology. Carcinoma, Small Cell / epidemiology. Carcinoma, Squamous Cell / epidemiology. Europe / epidemiology. Female. Humans. Incidence. Male. North America / epidemiology. Prevalence. Sex Characteristics

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15900604.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


87. Chen X, Zhao J, Guan YH, Lu S, Zuo CT, Hua FC, Lin X: Prognostic value of 2-[18F]fluoro-2-deoxy-D-glucose uptake as measured by PET scan in patients with non-small cell lung cancer. Mol Med Rep; 2008 Nov-Dec;1(6):889-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic value of 2-[18F]fluoro-2-deoxy-D-glucose uptake as measured by PET scan in patients with non-small cell lung cancer.
  • This study aimed to evaluate the prognostic value of 2-[18F]fluoro-2-deoxy-D-glucose (18F-FDG) uptake determined by positron emission tomography (PET) in patients with non-small cell lung cancer (NSCLC) in relation to disease stage and/or tumor histology.
  • A retrospective review of 144 patients with newly diagnosed lung cancer undergoing PET imaging was performed.
  • The latter was a better prognostic predictor in lung cancer patients with early-stage disease than in those at advanced stages.
  • SUVs provided stronger prognostic stratification in patients with adenocarcinoma than in those with squamous cell carcinoma (SCC).
  • Furthermore, the best choice of prognostic predictor differed between the two types of lung cancer: the SUV was best for SCC, while TNM stage was most significant for adenocarcinoma.
  • In conclusion, 18F-FDG uptake in primary lung lesions is an independent prognostic predictor in patients with NSCLC, especially those with adenocarcinoma or early-stage disease.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21479502.001).
  • [ISSN] 1791-2997
  • [Journal-full-title] Molecular medicine reports
  • [ISO-abbreviation] Mol Med Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


88. Vergou T, Stratigos AJ, Karapanagiotou EM, Matekovits AE, Dilana KD, Tsimboukis S, Antoniou C, Chasapi V, Syrigos KN: Facial hypertrichosis and trichomegaly developing in patients treated with the epidermal growth factor receptor inhibitor erlotinib. J Am Acad Dermatol; 2010 Aug;63(2):e56-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma / drug therapy. Hypertrichosis / chemically induced. Lung Neoplasms / drug therapy. Protein Kinase Inhibitors / adverse effects. Quinazolines / adverse effects
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Erlotinib Hydrochloride. Eyelashes. Face. Female. Humans. Middle Aged. Receptor, Epidermal Growth Factor / antagonists & inhibitors

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20633793.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protein Kinase Inhibitors; 0 / Quinazolines; DA87705X9K / Erlotinib Hydrochloride; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


89. Veeramachaneni NK, Battafarano RJ, Meyers BF, Zoole JB, Patterson GA: Risk factors for occult nodal metastasis in clinical T1N0 lung cancer: a negative impact on survival. Eur J Cardiothorac Surg; 2008 Mar;33(3):466-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk factors for occult nodal metastasis in clinical T1N0 lung cancer: a negative impact on survival.
  • BACKGROUND: The application of CT imaging has increased the identification of patients with clinical T1N0 (cT1N0) lung cancer.
  • The optimal management strategy for these early stage lung cancers remains unclear.
  • We analyzed the impact of occult nodal metastasis on cT1N0 lung cancer patients.
  • METHODS: We studied patients with cT1N0 lung cancer enrolled in our database from January 1995 to December 2002.
  • Because of the limitations of clinical staging, we believe that lobectomy and lymph node analysis should be offered to cT1N0 lung cancer patients to provide accurate staging and to optimize multimodality adjuvant treatment of lung cancer.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / secondary. Lung Neoplasms / pathology. Lymph Nodes / pathology
  • [MeSH-minor] Adenocarcinoma / mortality. Adenocarcinoma / secondary. Aged. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / secondary. Female. Humans. Logistic Models. Lymphatic Metastasis / diagnosis. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging. Risk Factors. Survival Analysis

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur J Cardiothorac Surg. 2008 Jun;33(6):1160-1 [18434182.001]
  • (PMID = 18249130.001).
  • [ISSN] 1010-7940
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


90. He LR, Zhao HY, Li BK, Zhang LJ, Liu MZ, Kung HF, Guan XY, Bian XW, Zeng YX, Xie D: Overexpression of AIB1 negatively affects survival of surgically resected non-small-cell lung cancer patients. Ann Oncol; 2010 Aug;21(8):1675-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of AIB1 negatively affects survival of surgically resected non-small-cell lung cancer patients.
  • BACKGROUND: The amplified in breast cancer 1 (AIB1) gene has been considered to play an oncogenic role in human cancers, but its clinical/prognostic significance in non-small-cell lung cancer (NSCLC) is still unclear.
  • PATIENTS AND METHODS: The methods of immunohistochemistry and FISH were utilized to examine protein expression and amplification of AIB1 in 230 informative surgically resected NSCLCs and in 30 samples of normal lung tissues.
  • AIB1 overexpression was associated with AIB1 gene amplification and cell proliferation but not related to estrogen receptor (ER)-alpha, ER-beta, progesterone receptor or androgen receptor status.
  • A positive correlation between AIB1 overexpression and an ascending pathologic node stage in lung adenocarcinoma (ADC) was observed (P = 0.043).
  • CONCLUSION: Overexpression of AIB1 might provide a selective advantage for lymph node metastasis of lung ADC and serve as a useful biomarker for poor prognosis for NSCLC patients.

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20064830.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Receptors, Androgen; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; EC 2.3.1.48 / NCOA3 protein, human; EC 2.3.1.48 / Nuclear Receptor Coactivator 3
  •  go-up   go-down


91. Shimizu K, Yamada K, Saito H, Noda K, Nakayama H, Kameda Y, Nakata K: Surgically curable peripheral lung carcinoma: correlation of thin-section CT findings with histologic prognostic factors and survival. Chest; 2005 Mar;127(3):871-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgically curable peripheral lung carcinoma: correlation of thin-section CT findings with histologic prognostic factors and survival.
  • STUDY OBJECTIVES: To define characteristics of surgically curable, early cancers of the lung, we retrospectively studied relationships between thin-section CT (TS-CT) scans, pathologic features, and outcome data in 287 patients with resected small-diameter (< 20 mm) peripheral lung carcinoma.
  • Cases included 260 adenocarcinomas, 16 squamous cell carcinomas, 6 small cell carcinomas, 3 large cell carcinomas, and 2 others.
  • All non-adenocarcinoma cases (n = 25) had a solid-density pattern, with 4% pleural involvement, 52% vascular invasion, and 44% lymphatic permeation.
  • The overall 5-year survival rate for non-adenocarcinoma was 60%, similar to that for solid-density adenocarcinoma.
  • CONCLUSIONS: When peripheral lung cancers < 20 mm in diameter show air-containing patterns on TS-CT images, surgical outcomes may be favorable with curable disease.
  • [MeSH-major] Carcinoma / mortality. Lung / pathology. Lung / radiography. Lung Neoplasms / mortality

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15764770.001).
  • [ISSN] 0012-3692
  • [Journal-full-title] Chest
  • [ISO-abbreviation] Chest
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


92. Bai XY, Shen H: [Quantitative analysis of thyroid transcription factor-1 mRNA expressions in primary lung cancer and its metastatic foci]. Nan Fang Yi Ke Da Xue Xue Bao; 2008 Jan;28(1):20-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Quantitative analysis of thyroid transcription factor-1 mRNA expressions in primary lung cancer and its metastatic foci].
  • OBJECTIVE: To observe the expression of thyroid transcription factor-1 (TTF-1) mRNA in human normal adult type II alveolar epithelial cells, embryonic alveolar epithelial cells, and primary lung carcinoma and lymph nodes, thereby exploring the role of TTF-1 mRNA expression in the tumorigenesis, development and metastasis of lung carcinoma.
  • RESULTS: TTF-1 mRNA expression was significantly less intense in embryonic lung than in normal adult lung tissues (P= 0.000), and the two tissues both had significantly greater expression than lung adenocarcinoma, squamous cell carcinoma, small cell carcinoma and large cell carcinoma (P=0.000).
  • Lung adenocarcinoma and small cell carcinoma, with similar expression intensity (P= 0.068), showed stronger expression than squamous cell carcinoma and large cell carcinoma (P=0.000), and squamous cell carcinoma showed stronger expression than large cell carcinoma (P=0.018).
  • In lung adenocarcinoma, squamous cell carcinoma and large cell carcinoma, the intensity of TTF-1 mRNA expression was stronger in lymph node metastases than in the primary foci (P=0.003, P=0.000, P=0.019, respectively).
  • The lymph node metastases had more intense expression than the primary foci of small cell lung carcinoma (P=0.078).
  • The intensity of TTF-1 mRNA expression was greater in primary lung carcinomas with lymph node metastases than in those without metastases (P=0.026).
  • CONCLUSION: The amount of TTF-1 mRNA expression lowers in the order of normal adult lung, embryonic lung and lung carcinoma tissues.
  • In lung carcinomas, TTF-1 mRNA expression differs between the histological types, high in lung adenocarcinoma and small cell carcinoma and rather low in squamous cell carcinoma and large cell carcinoma.
  • Strong expression of TTF-1 mRNA often indicates high likeliness of lung carcinoma metastasis, and highlights the high metastatic potentials of lung adenocarcinoma, squamous cell carcinoma and large cell carcinoma.
  • [MeSH-major] Carcinoma, Squamous Cell / genetics. Lung Neoplasms / genetics. Nuclear Proteins / genetics. Transcription Factors / genetics
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Female. Humans. In Situ Hybridization. Lymphatic Metastasis. Male. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. Thyroid Gland / metabolism. Tissue Array Analysis / methods

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Thyroid Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18227018.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Nuclear Proteins; 0 / RNA, Messenger; 0 / Transcription Factors; 0 / thyroid nuclear factor 1
  •  go-up   go-down


93. Su Y, Bai M, Zhu LP, Jin Y, Zhang XJ, Zhou Q: [Pirh2 shRNA mediated by psiRNA-hH1 vector plasmid effectively inhibits the proliferation of lung carcinoma cells: in vitro and in vivo experiments]. Zhonghua Yi Xue Za Zhi; 2007 May 8;87(17):1199-203
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pirh2 shRNA mediated by psiRNA-hH1 vector plasmid effectively inhibits the proliferation of lung carcinoma cells: in vitro and in vivo experiments].
  • OBJECTIVE: To investigate the role of P53 induced RING-H2 protein (pirh2) for proliferation of lung cancer cell in vitro and vivo.
  • METHODS: Immunohistochemistry was applied to detect the expression of pirh2 protein in 53 specimens of lung cancer resected during operation.
  • Human lung adenocarcinoma cells of the line A549 were cultured.
  • The ability of cell proliferation was analyzed with cell counting kit-8 (CCK-8) method.
  • RESULTS: Forty-two of the 53 C lung cancer specimens (79.2%) showed expression of pirh2 protein.
  • The weight of the tumors taken pout of the rats of the pirh2 shRNA group was 0.59 +/- 0.16 g, significantly lower than that of the normal A549 cell group (1.66 g +/- 0.21 g, t = 6.27, P < 0.05).
  • But there was no significant difference in the tumor weight between the normal A549 cell group and psiRNA-Con group.
  • CONCLUSION: pirh2 may be a critical factor in lung cancer formation.
  • The successfully constructed shRNA targeting pirh2 efficiently decreases its expression in lung cancer cells and inhibits the growth of the lung cancer cells.
  • [MeSH-major] Lung Neoplasms / genetics. Plasmids / genetics. RNA, Small Interfering / genetics. Ubiquitin-Protein Ligases / genetics
  • [MeSH-minor] Animals. Blotting, Western. Cell Line, Tumor. Cell Proliferation / drug effects. Genetic Vectors / genetics. Humans. Immunohistochemistry. RNA Interference. Rats. Rats, Nude. Reverse Transcriptase Polymerase Chain Reaction. Sincalide / pharmacology. Transfection. Tumor Burden. Xenograft Model Antitumor Assays / methods. Zinc Fingers

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17686242.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / RNA, Small Interfering; EC 6.3.2.19 / RCHY1 protein, human; EC 6.3.2.19 / Ubiquitin-Protein Ligases; M03GIQ7Z6P / Sincalide
  •  go-up   go-down


94. Nakajima T, Yasufuku K, Nakajima M, Baba M, Yoshikawa K, Kamada T, Hiroshima K, Nakatani Y, Fujisawa T, Yoshino I: Endobronchial ultrasound-guided transbronchial needle aspiration for lymph node staging in patients with non-small cell lung cancer in non-operable patients pursuing radiotherapy as a primary treatment. J Thorac Oncol; 2010 May;5(5):606-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endobronchial ultrasound-guided transbronchial needle aspiration for lymph node staging in patients with non-small cell lung cancer in non-operable patients pursuing radiotherapy as a primary treatment.
  • The aim of this study was to evaluate the effectiveness of endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) for lymph node staging in patients with non-small cell lung cancer before CIRT.
  • METHODS: From April 2005 to December 2007, 49 patients with non-small cell lung cancer considered for CIRT with abnormal positron emission tomography-computed tomography (PET-CT) accumulations in the mediastinum and/or hilum were evaluated by EBUS-TBNA.
  • By histology, 26 patients had adenocarcinoma, 19 had squamous cell carcinoma, and four had other histologies.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / pathology. Carcinoma, Non-Small-Cell Lung / radiotherapy. Endosonography. Lung Neoplasms / pathology. Lung Neoplasms / radiotherapy. Lymph Nodes / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / radiography. Adenocarcinoma / radiotherapy. Adenocarcinoma / ultrasonography. Aged. Aged, 80 and over. Biopsy, Fine-Needle. Carcinoma, Large Cell / pathology. Carcinoma, Large Cell / radiography. Carcinoma, Large Cell / radiotherapy. Carcinoma, Large Cell / ultrasonography. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiography. Carcinoma, Squamous Cell / radiotherapy. Carcinoma, Squamous Cell / ultrasonography. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Positron-Emission Tomography. Prognosis. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20354458.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


95. Zhang X, Chang A: Somatic mutations of the epidermal growth factor receptor and non-small-cell lung cancer. J Med Genet; 2007 Mar;44(3):166-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Somatic mutations of the epidermal growth factor receptor and non-small-cell lung cancer.
  • Frequent overexpression of epidermal growth factor receptor (EGFR) in non-small-cell lung cancer (NSCLC) makes EGFR a new therapeutic target.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / genetics. Genes, erbB-1. Lung Neoplasms / genetics. Mutation. Receptor, Epidermal Growth Factor / physiology
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / enzymology. Adenocarcinoma / genetics. Cell Transformation, Neoplastic / genetics. Clinical Trials, Phase II as Topic. DNA Mutational Analysis. DNA, Neoplasm / genetics. Double-Blind Method. Drug Delivery Systems. Drug Design. Drug Resistance, Neoplasm. Ethnic Groups / genetics. Exons / genetics. Female. Genes, p53. Genes, ras. Genotype. Humans. Male. Mutagenesis, Insertional. Mutation, Missense. Protein Structure, Tertiary / genetics. Quinazolines / pharmacology. Quinazolines / therapeutic use. Randomized Controlled Trials as Topic. Sequence Deletion. Smoking

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Oncol. 2001 May;18(5):1023-6 [11295051.001]
  • [Cites] Oncogene. 2000 Dec 27;19(56):6550-65 [11426640.001]
  • [Cites] Ann Oncol. 2001 Jun;12(6):745-60 [11484948.001]
  • [Cites] CA Cancer J Clin. 2001 Jan-Feb;51(1):15-36 [11577478.001]
  • [Cites] Eur J Cancer. 2001 Sep;37 Suppl 4:S9-15 [11597399.001]
  • [Cites] Eur Respir J. 2001 Dec;18(6):1059-68 [11829087.001]
  • [Cites] Lancet Oncol. 2001 Sep;2(9):533-43 [11905707.001]
  • [Cites] Am J Pathol. 2002 Jun;160(6):2055-61 [12057910.001]
  • [Cites] Cancer Cell. 2002 Aug;2(2):117-25 [12204532.001]
  • [Cites] Hum Mutat. 2003 Mar;21(3):229-39 [12619108.001]
  • [Cites] J Clin Oncol. 2003 Jun 15;21(12):2237-46 [12748244.001]
  • [Cites] Oncologist. 2003;8(4):303-6 [12897327.001]
  • [Cites] JAMA. 2003 Oct 22;290(16):2149-58 [14570950.001]
  • [Cites] Science. 2004 Apr 30;304(5671):658-9 [15118127.001]
  • [Cites] N Engl J Med. 2004 May 20;350(21):2129-39 [15118073.001]
  • [Cites] Science. 2004 Jun 4;304(5676):1497-500 [15118125.001]
  • [Cites] Clin Cancer Res. 2004 Jun 15;10(12 Pt 2):4227s-4232s [15217963.001]
  • [Cites] Science. 2004 Aug 20;305(5687):1163-7 [15284455.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Sep 7;101(36):13306-11 [15329413.001]
  • [Cites] Cancer Res. 2004 Oct 15;64(20):7241-4 [15492241.001]
  • [Cites] J Epidemiol Community Health. 1978 Dec;32(4):303-13 [744822.001]
  • [Cites] Proc Natl Acad Sci U S A. 1980 Jun;77(6):3600-4 [6968072.001]
  • [Cites] Int J Cancer. 2006 Feb 15;118(4):963-9 [16152581.001]
  • [Cites] PLoS Med. 2005 Nov;2(11):e313 [16187797.001]
  • [Cites] Br J Cancer. 2006 Mar 27;94(6):896-903 [16552419.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 May 16;103(20):7817-22 [16672372.001]
  • [Cites] Clin Cancer Res. 2006 Jul 1;12(13):3908-14 [16818686.001]
  • [Cites] J Clin Oncol. 2006 Jul 20;24(21):3340-6 [16785471.001]
  • [Cites] Cancer Sci. 2006 Aug;97(8):753-9 [16863509.001]
  • [Cites] Int J Cancer. 2006 Nov 15;119(10):2353-8 [16921488.001]
  • [Cites] J Clin Invest. 2006 Oct;116(10):2695-706 [16906227.001]
  • [Cites] Br J Cancer. 2006 Oct 23;95(8):998-1004 [17047648.001]
  • [Cites] Ann Oncol. 1999;10 Suppl 5:S3-6 [10582131.001]
  • [Cites] J Thorac Cardiovasc Surg. 1999 Dec;118(6):1136-52 [10595998.001]
  • [Cites] Ann Epidemiol. 1993 Jul;3(4):417-24 [8275219.001]
  • [Cites] Cancer. 1995 Jan 1;75(1 Suppl):191-202 [8000996.001]
  • [Cites] Crit Rev Oncol Hematol. 1995 Jul;19(3):183-232 [7612182.001]
  • [Cites] Diagn Mol Pathol. 1995 Dec;4(4):249-55 [8634780.001]
  • [Cites] Biochem J. 1997 Jun 15;324 ( Pt 3):855-61 [9210410.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1997 Oct;6(10):841-7 [9332768.001]
  • [Cites] Br J Cancer. 1998 Feb;77(4):663-9 [9484827.001]
  • [Cites] Biochim Biophys Acta. 1998 Aug 19;1378(1):F21-59 [9739759.001]
  • [Cites] Clin Cancer Res. 1996 Feb;2(2):411-8 [9816185.001]
  • [Cites] Epidemiol Rev. 1998;20(2):218-36 [9919440.001]
  • [Cites] Cancer Res. 2004 Dec 15;64(24):8919-23 [15604253.001]
  • [Cites] Clin Cancer Res. 2004 Dec 15;10(24):8195-203 [15623594.001]
  • [Cites] Cancer Res. 2005 Jan 1;65(1):226-35 [15665299.001]
  • [Cites] J Clin Oncol. 2005 Feb 1;23(4):857-65 [15681531.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):1167-73 [15709185.001]
  • [Cites] N Engl J Med. 2005 Feb 24;352(8):786-92 [15728811.001]
  • [Cites] J Natl Cancer Inst. 2005 Mar 2;97(5):339-46 [15741570.001]
  • [Cites] J Clin Oncol. 2005 Apr 10;23(11):2513-20 [15738541.001]
  • [Cites] J Natl Cancer Inst. 2005 May 4;97(9):643-55 [15870435.001]
  • [Cites] Clin Cancer Res. 2005 Jun 1;11(11):4182-90 [15930355.001]
  • [Cites] Respiration. 2005 May-Jun;72(3):313-30 [15942304.001]
  • [Cites] PLoS Med. 2005 Mar;2(3):e73 [15737014.001]
  • [Cites] J Mol Diagn. 2005 Aug;7(3):396-403 [16049312.001]
  • [Cites] Br J Cancer. 2005 Aug 8;93(3):355-63 [16052218.001]
  • [Cites] Cancer Res. 2005 Aug 15;65(16):7276-82 [16105816.001]
  • [Cites] Clin Cancer Res. 2005 Aug 15;11(16):5878-85 [16115929.001]
  • [Cites] Oncol Rep. 2000 May-Jun;7(3):603-7 [10767376.001]
  • [Cites] Cell. 2000 Oct 13;103(2):211-25 [11057895.001]
  • [Cites] Science. 1985 Dec 6;230(4730):1132-9 [2999974.001]
  • [Cites] Annu Rev Biochem. 1987;56:881-914 [3039909.001]
  • [Cites] Clin Physiol Biochem. 1987;5(3-4):130-9 [3040317.001]
  • [Cites] Nature. 1988 Dec 22-29;336(6201):790-2 [3205307.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Dec;86(23):9193-7 [2687875.001]
  • [Cites] Jpn J Cancer Res. 1990 Aug;81(8):773-9 [2168866.001]
  • [Cites] Environ Health Perspect. 1990 Jul;87:19-26 [2269225.001]
  • [Cites] Cancer Invest. 1991;9(5):553-62 [1933488.001]
  • [Cites] J Pathol. 1992 Nov;168(3):269-73 [1361525.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Mar 1;90(5):1746-50 [8383326.001]
  • [Cites] Cancer Res. 1993 Jul 15;53(14):3217-20 [8391918.001]
  • [Cites] Anticancer Res. 1993 Jul-Aug;13(4):1133-7 [8394672.001]
  • [Cites] J Clin Oncol. 2005 Sep 1;23(25):5900-9 [16043828.001]
  • [Cites] Respirology. 2005 Sep;10(4):408-17 [16135162.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):7568-72 [16140919.001]
  • [Cites] Oncologist. 2005 Sep;10(8):579-89 [16177282.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):6838-45 [15998906.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):6829-37 [15998907.001]
  • [Cites] Int J Cancer. 2006 Jan 15;118(2):257-62 [16231326.001]
  • [Cites] Nat Genet. 2005 Dec;37(12):1315-6 [16258541.001]
  • [Cites] Clin Cancer Res. 2006 Jan 1;12(1):43-8 [16397022.001]
  • [Cites] Nat Clin Pract Oncol. 2006 Jan;3(1):50-7; quiz 1 p following 57 [16407879.001]
  • [Cites] Eur Respir J. 2000 Nov;16(5):991-6 [11153605.001]
  • [Cites] Nat Rev Mol Cell Biol. 2001 Feb;2(2):127-37 [11252954.001]
  • (PMID = 17158592.001).
  • [ISSN] 1468-6244
  • [Journal-full-title] Journal of medical genetics
  • [ISO-abbreviation] J. Med. Genet.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Quinazolines; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; S65743JHBS / gefitinib
  • [Number-of-references] 87
  • [Other-IDs] NLM/ PMC2598028
  •  go-up   go-down


96. Honda O, Kawai M, Gyobu T, Kawata Y, Johkoh T, Sekiguchi J, Tomiyama N, Yoshida S, Sumikawa H, Inoue A, Yanagawa M, Daimon T, Nakamura H: Reproducibility of temporal volume change in CT of lung cancer: comparison of computer software and manual assessment. Br J Radiol; 2009 Aug;82(981):742-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reproducibility of temporal volume change in CT of lung cancer: comparison of computer software and manual assessment.
  • Three observers manually evaluated whether tumour volume was increasing, if it was unchanged, or if it had decreased in size in 2 serial CT examinations of 45 solid lung cancers.
  • Inconsistency is often seen in manual assessment; in contrast, evaluation using volumetric software has good reproducibility, even when the relative change in tumour volume is small.
  • [MeSH-major] Adenocarcinoma / radiography. Carcinoma, Squamous Cell / radiography. Lung Neoplasms / radiography. Tumor Burden

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19332515.001).
  • [ISSN] 1748-880X
  • [Journal-full-title] The British journal of radiology
  • [ISO-abbreviation] Br J Radiol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


97. Yi H, Cho HJ, Cho SM, Lee DG, Abd El-Aty AM, Yoon SJ, Bae GW, Nho K, Kim B, Lee CH, Kim JS, Bartlett MG, Shin HC: Pharmacokinetic properties and antitumor efficacy of the 5-fluorouracil loaded PEG-hydrogel. BMC Cancer; 2010;10:211
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • For the pharmacodynamic study, a human non-small-cell lung adenocarcinoma (NSCLC) cell line, A549 was inoculated to male nude mice with a cell density of 3 x 10(6).
  • [MeSH-major] Antimetabolites, Antineoplastic / pharmacokinetics. Carcinoma, Non-Small-Cell Lung / drug therapy. Drug Carriers. Fluorouracil / pharmacokinetics. Hydrogels. Lung Neoplasms / drug therapy. Polyethylene Glycols / chemistry
  • [MeSH-minor] Animals. Cell Line, Tumor. Chemistry, Pharmaceutical. Drug Compounding. Drug Implants. Humans. Male. Mice. Mice, Inbred BALB C. Mice, Nude. Rats. Rats, Sprague-Dawley. Solubility. Tumor Burden. Xenograft Model Antitumor Assays

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1982 Nov;42(11):4413-20 [7127282.001]
  • [Cites] Nature. 1980 May 29;285(5763):326-9 [7374784.001]
  • [Cites] Cancer. 1980 Mar 15;45(5 Suppl):1144-58 [6766799.001]
  • [Cites] Cancer Chemother Pharmacol. 1986;16(1):64-6 [3940221.001]
  • [Cites] Cancer Treat Rep. 1985 Dec;69(12):1391-8 [4075316.001]
  • [Cites] Semin Surg Oncol. 1987;3(3):190-214 [3310182.001]
  • [Cites] Cancer Chemother Pharmacol. 1988;22(1):58-62 [2969305.001]
  • [Cites] Br J Cancer. 1989 Feb;59(2):287-90 [2930694.001]
  • [Cites] Antimicrob Agents Chemother. 1995 Apr;39(4):839-45 [7785981.001]
  • [Cites] J Natl Cancer Inst. 1996 May 15;88(10):668-74 [8627643.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):301-8 [9440757.001]
  • [Cites] Clin Cancer Res. 1995 Jun;1(6):615-20 [9816023.001]
  • [Cites] Nature. 1957 Mar 30;179(4561):663-6 [13418758.001]
  • [Cites] Cancer Chemother Rep. 1962 Dec;25:87-9 [13981540.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15611-6 [16223882.001]
  • [Cites] J Control Release. 2006 May 30;112(3):333-42 [16650910.001]
  • [Cites] Crit Rev Oncol Hematol. 1999 Mar;30(1):71-9 [10439055.001]
  • [Cites] J Pharm Pharmacol. 2000 Nov;52(11):1319-25 [11186239.001]
  • [Cites] Oncogene. 2001 Apr 26;20(18):2254-63 [11402320.001]
  • [Cites] Curr Pharm Biotechnol. 2000 Sep;1(2):137-64 [11467334.001]
  • [Cites] Cancer. 2002 Oct 15;95(8):1629-36 [12365009.001]
  • [Cites] Biomaterials. 2003 Jan;24(1):11-8 [12417173.001]
  • [Cites] Cancer Res. 1972 Dec;32(12):2717-9 [4566290.001]
  • [Cites] Cancer. 1975 Jul;36(1):123-8 [1203840.001]
  • [Cites] Cancer Res. 1976 Jul;36(7 PT 1):2182-8 [1277123.001]
  • [Cites] Cancer. 1977 Jan;39(1):34-40 [318916.001]
  • (PMID = 20482808.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Carriers; 0 / Drug Implants; 0 / Hydrogels; 30IQX730WE / Polyethylene Glycols; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2889891
  •  go-up   go-down


98. Burdak-Rothkamm S, Rübe CE, Nguyen TP, Ludwig D, Feldmann K, Wiegel T, Rübe C: Radiosensitivity of tumor cell lines after pretreatment with the EGFR tyrosine kinase inhibitor ZD1839 (Iressa). Strahlenther Onkol; 2005 Mar;181(3):197-204
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiosensitivity of tumor cell lines after pretreatment with the EGFR tyrosine kinase inhibitor ZD1839 (Iressa).
  • MATERIAL AND METHODS: Three tumor cell lines (A549, H596, FaDu) were exposed to ionizing radiation, treatment with ZD1839, and combined treatment.
  • Clonogenic cell survival was determined by colony assays, EGFR and transforming growth factor-(TGF-)alpha expression by quantitative real-time reverse transcription-polymerase chain reaction (RT-PCR), cell cycle distribution and apoptosis by flow cytometry.
  • Both cell lines expressed moderate amounts of EGFR mRNA and very low levels of TGF-alpha mRNA.
  • FaDu cells expressed relatively high amounts of EGFR and TGF-alpha transcripts and showed marked inhibition of clonogenic growth, reduction of S-phase cells, and induction of apoptosis after treatment with 1 microM ZD1839 and combined treatment.
  • CONCLUSION: The sensitivity to ZD1839 correlated with the EGFR expression level, an inhibition of cell proliferation, and induction of apoptosis in the cell lines analyzed.
  • [MeSH-minor] Adenocarcinoma. Carcinoma, Non-Small-Cell Lung. Carcinoma, Squamous Cell. Cell Line, Tumor. Humans. Lung Neoplasms

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15756525.001).
  • [ISSN] 0179-7158
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Protein Kinase Inhibitors; 0 / Quinazolines; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; S65743JHBS / gefitinib
  •  go-up   go-down


99. Suemitsu R, Ueda H, Shikada Y, Ondo K, Yoshino I, Maehara Y: Relationship of tumor size to survival in patients with pT2N0 lung cancer. Asian Cardiovasc Thorac Ann; 2006 Feb;14(1):30-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relationship of tumor size to survival in patients with pT2N0 lung cancer.
  • Lung cancer extending beyond 3 cm in diameter without lymph node or distant metastasis is defined as T2.
  • The purpose of this study was to analyze the prognosis based on tumor size for patients with resected T2N0M0 non-small cell lung cancer.
  • The 268 patients who underwent complete resection of a lung tumor > 3 cm in diameter were reviewed retrospectively.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Large Cell / pathology. Carcinoma, Non-Small-Cell Lung / pathology. Carcinoma, Squamous Cell / pathology. Tumor Burden

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16432115.001).
  • [ISSN] 1816-5370
  • [Journal-full-title] Asian cardiovascular & thoracic annals
  • [ISO-abbreviation] Asian Cardiovasc Thorac Ann
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


100. Imai H, Sunaga N, Shimizu Y, Kakegawa S, Shimizu K, Sano T, Ishizuka T, Oyama T, Saito R, Minna JD, Mori M: Clinicopathological and therapeutic significance of CXCL12 expression in lung cancer. Int J Immunopathol Pharmacol; 2010 Jan-Mar;23(1):153-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological and therapeutic significance of CXCL12 expression in lung cancer.
  • However, CXCL12 expression and its role in lung cancer are not fully elucidated.
  • Here we examined the expression of CXCL12 in 54 lung cancer cell lines consisting of 23 small cell lung cancers (SCLCs) and 31 non-small cell lung cancers (NSCLCs).
  • CXCL12 was overexpressed in lung cancer cell lines compared to non-malignant human bronchial epithelial cell lines (N = 6).
  • We also examined CXCL12 expression in 89 NSCLC specimens and found that CXCL12 expression was significantly higher in tumor specimens from female patients, non-smokers and adenocarcinoma patients.
  • Small interfering RNAs targeting CXCL12 inhibited cellular proliferation, colony formation and migration of CXCL12-overexpressing lung cancer cells; however, this inhibition did not occur in lung cancer cells that lacked CXCL12.
  • Furthermore, the anti-CXCL12 neutralizing antibody mediated inhibitory effects in three lung cancer cell lines that overexpressed CXCL12, but not in two CXCL12 non-expressing lung cancer cell lines nor two non-malignant bronchial epithelial cell lines.
  • The present study demonstrates that: CXCL12 is concomitantly overexpressed with CXCR4 or CXCR7 in lung cancers; CXCL12 is highly expressed in NSCLCs from females, non-smokers and adenocarcinoma patients; and disruption of CXCL12 inhibits the growth and migration of lung cancer cells.
  • Our findings indicate that CXCL12 is required for tumor growth and provide a rationale for the anti-CXCL12 treatment strategy in lung cancer.
  • [MeSH-major] Chemokine CXCL12 / physiology. Lung Neoplasms / pathology
  • [MeSH-minor] Carcinoma, Non-Small-Cell Lung / immunology. Carcinoma, Non-Small-Cell Lung / pathology. Cell Line, Tumor. Cell Movement. Cell Proliferation. Female. Humans. Male. RNA, Messenger / analysis. RNA, Small Interfering / genetics. Receptor, Epidermal Growth Factor / physiology. Receptors, CXCR / genetics. Receptors, CXCR4 / genetics

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2001 Mar 1;410(6824):50-6 [11242036.001]
  • [Cites] J Immunol. 2006 Nov 15;177(10):6983-90 [17082613.001]
  • [Cites] Cancer Cell. 2002 Feb;1(1):49-52 [12086887.001]
  • [Cites] Cancer Res. 2002 Nov 1;62(21):6304-11 [12414661.001]
  • [Cites] Am J Respir Crit Care Med. 2003 Jun 15;167(12):1676-86 [12626353.001]
  • [Cites] Oncogene. 2003 Nov 6;22(50):8093-101 [14603250.001]
  • [Cites] Mol Cancer Ther. 2004 Jan;3(1):29-37 [14749473.001]
  • [Cites] Cancer Res. 2004 May 1;64(9):3137-43 [15126351.001]
  • [Cites] Cancer Res. 2004 Jun 15;64(12):4277-85 [15205342.001]
  • [Cites] Nat Rev Cancer. 2004 Jul;4(7):540-50 [15229479.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Jul 30;320(3):656-63 [15240098.001]
  • [Cites] J Cell Biochem Suppl. 1996;24:32-91 [8806092.001]
  • [Cites] Cytokine Growth Factor Rev. 1996 Jun;7(1):47-64 [8864354.001]
  • [Cites] Nature. 1997 Jun 5;387(6633):620-4 [9177352.001]
  • [Cites] Cancer Res. 2004 Dec 15;64(24):9027-34 [15604268.001]
  • [Cites] Cancer Res. 2005 Jan 15;65(2):465-72 [15695388.001]
  • [Cites] J Natl Cancer Inst. 2005 Mar 2;97(5):339-46 [15741570.001]
  • [Cites] Cell. 2005 May 6;121(3):335-48 [15882617.001]
  • [Cites] J Biol Chem. 2005 Jun 10;280(23):22473-81 [15802268.001]
  • [Cites] Oncogene. 2005 Jun 23;24(27):4462-71 [15806155.001]
  • [Cites] Exp Cell Res. 2005 Aug 15;308(2):241-53 [15921680.001]
  • [Cites] J Biol Chem. 2005 Oct 21;280(42):35760-6 [16107333.001]
  • [Cites] Clin Cancer Res. 2005 Dec 1;11(23):8273-80 [16322285.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] Mol Cancer Res. 2007 Jan;5(1):21-33 [17259344.001]
  • [Cites] Am J Physiol Cell Physiol. 2007 Mar;292(3):C987-95 [16943240.001]
  • [Cites] Mol Cancer Res. 2007 Jul;5(7):685-94 [17634424.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Oct 2;104(40):15735-40 [17898181.001]
  • [Cites] Carcinogenesis. 2008 Jan;29(1):35-43 [17916907.001]
  • [Cites] J Biol Chem. 2008 Feb 15;283(7):4283-94 [18057003.001]
  • [Cites] Int J Oncol. 2008 Jul;33(1):113-9 [18575756.001]
  • [Cites] Clin Cancer Res. 2008 Aug 15;14(16):5022-32 [18698020.001]
  • [Cites] Br J Cancer. 2008 Nov 4;99(9):1493-501 [18854833.001]
  • [Cites] Int J Immunopathol Pharmacol. 2009 Jan-Mar;22(1):43-51 [19309551.001]
  • [Cites] Cancer. 2009 Jun 1;115(11):2580-93 [19309748.001]
  • [Cites] J Immunol. 2001 Oct 15;167(8):4747-57 [11591806.001]
  • (PMID = 20378003.001).
  • [ISSN] 0394-6320
  • [Journal-full-title] International journal of immunopathology and pharmacology
  • [ISO-abbreviation] Int J Immunopathol Pharmacol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50 CA070907
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CXCL12 protein, human; 0 / CXCR4 protein, human; 0 / CXCR7 protein, human; 0 / Chemokine CXCL12; 0 / RNA, Messenger; 0 / RNA, Small Interfering; 0 / Receptors, CXCR; 0 / Receptors, CXCR4; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  • [Other-IDs] NLM/ NIHMS381453; NLM/ PMC3368436
  •  go-up   go-down






Advertisement